Decera Clinical Education Oncology Podcast

Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer

support@deceraclinical.com (Danielle Roman PharmD BCOP, Jordan Hill PharmD BCOP) — Tue, 14 Apr 2026 19:56:16 +0000

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including:

Practical strategies for monitoring and managing key adverse events associated with abemaciclib, ribociclib, and palbociclib, such as diarrhea, neutropenia, hepatotoxicity, and QT prolongation
How dose interruptions and dose reductions can help improve tolerability while maintaining clinical benefit
Real-world approaches to patient education, toxicity counseling, and communication that can improve adherence and persistence with oral CDK4/6 inhibitor therapy
Additional considerations such as financial toxicity, coordination with specialty pharmacy, and practical tools to help patients stay on therapy over the long term

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Oncology Clinical Pharmacy Specialist
Allegheny Health Network
Pittsburgh, Pennsylvania

Jordan Hill, PharmD, BCOP
Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Link to full program:
https://bit.ly/4cIYca6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

support@deceraclinical.com (Matthew Gubens MD MS FASCO, Helena Yu MD) — Mon, 13 Apr 2026 15:40:27 +0000

In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including

The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan
Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape
Practical advice on associated adverse events and additional considerations,
A look at future directions on the horizon, such as first-line studies and predictive biomarkers

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Matthew Gubens, MD, MS, FASCO
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Helena Yu, MD
Professor of Medicine
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program:
https://bit.ly/41vAnfH

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer

support@deceraclinical.com (Amit Mahipal MD MPH, Shubham Pant MD) — Mon, 13 Apr 2026 15:01:24 +0000

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including:

A brief overview of BTC and GEA
Notable findings from a recent survey of healthcare professionals on BTC and GEA
Case studies on recommended management of patients with BTC or GEA
Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice
Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA
Key ongoing trials of HER2-directed therapies in BTC and GEA

Presenters:

Amit Mahipal, MD, MPH
Chief, GI Medical Oncology Program
Professor of Medicine
Ruth and Goodman Endowed Chair in GI Oncology
H Seidman Cancer Center and Case Western Reserve University
Cleveland, Ohio

Shubham Pant, MD
Professor
Department of Gastrointestinal Medical Oncology
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Link to full program:
https://bit.ly/4ckcBrZ

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC

support@deceraclinical.com (Aditya Bardia MD MPH FASCO, Ruta Rao MD) — Thu, 26 Mar 2026 13:13:16 +0000

In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:

Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important
ADCs for HER2-negative/ultralow/low MBC
Patient communication: best practices in discussing treatment goals and potential AEs

Presenters:

Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine
University of California
Los Angeles, California

Ruta Rao, MD
Medical Director, Rush University Cancer Center
Professor of Medicine
Rush University Medical Center
Chicago, Illinois

Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Link to full program:
https://bit.ly/47JLtBt

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer

Wed, 25 Mar 2026 20:46:41 +0000

Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients.

Presenters:

Ann Marie Siney, RN, MSN, ANP-BC
Division of Hematology/Oncology
UCLA Health
Santa Monica, California

Kathleen Boyle, DScPAS, PA-C
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program:
https://bit.ly/4spkxiC

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer

Wed, 25 Mar 2026 14:06:13 +0000

Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of biomarker testing results to practice.

Presenters:

Sara Traverso, MMS, PA-C
Physician Assistant
Northwestern Medicine
Robert H. Lurie Comprehensive Cancer Center
Genitourinary Oncology
Chicago, Illinois

Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Northwestern Medicine
Chicago, Illinois

Link to full program:
https://bit.ly/3PB4ZJR

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026

support@deceraclinical.com (Sam S. Chang MD MBA, Matthew D. Galsky MD) — Mon, 23 Mar 2026 19:19:56 +0000

In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including:

New treatment options for BCG-unresponsive non–muscle-invasive bladder cancer
Intravesical therapies such as nadofaragene and N-803
The role of ctDNA in measurable residual disease detection

Presenters:

Sam S. Chang, MD, MBA
Patricia and Rodes Hart Chair of Urologic Surgery
Chief Surgical Officer
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Matthew D. Galsky, MD
Lillian and Howard Stratton Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Co-Leader, Cancer Clinical Investigation Program
Associate Director for Translational Research
Tisch Cancer Institute
New York, New York

Link to full program:
https://bit.ly/479RgQn

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization

Fri, 20 Mar 2026 17:38:27 +0000

In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.

Presenters:

Rodney Hunter, PharmD, BCOP
Director of Clinical Services
Memorial Hermann Texas Medical Center
Clinical Pharmacy Specialist
University of Texas Health Memorial Hermann Cancer Center
Professor
Texas Southern University College of Pharmacy and Health Sciences
Clinical Adjunct Professor
McGovern Medical School
Houston, Texas

Julia L. Ziegengeist, PharmD, BCOP
Clinical Pharmacist Specialist, Breast Medical Oncology
Levine Cancer, Atrium Health
Charlotte, North Carolina

Link to full program:
https://bit.ly/46SPGlU

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL

Wed, 11 Mar 2026 16:56:12 +0000

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including:

How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe
Practical sequencing decisions after disease progression
Emerging BTK degradersas a promising option for heavily pretreated patients

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Presenters:

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Nelson Hamerschlak, MD, PhD
Head of the Department of Hematology, BMT and Clinical Cell Therapy
Einstein Hospital Israelita
Sao Paulo, Brazil

Stephen Stilgenbauer, MD
Medical Director, Comprehensive Cancer Center Ulm (CCCU)
Head, Early Clinical Trials Unit (ECTU)
Head, Division of CLL Department of Internal Medicine III
Comprehensive Cancer Center Ulm (CCCU)
University of Medical Center Ulm
Ulm, Germany

Link to the full program:
https://bit.ly/4rsZlqF

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast

support@deceraclinical.com (Sara M. Tolaney MD MPH, Virginia Kaklamani MD DSc) — Mon, 9 Mar 2026 18:50:16 +0000

Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,

about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium.

Presenters:

Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Virginia Kaklamani, MD, DSc
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Link to full program:
https://bit.ly/46Qv9OK

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

support@deceraclinical.com (Luis Paz-Ares MD PhD, Christine Bestvina MD) — Mon, 9 Mar 2026 17:28:43 +0000

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:

Clinical outcomes and limitations of first-generation KRAS G12C inhibitors
Key unmet needs, including primary and acquired resistance
Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy

Presenters:

Luis Paz-Ares, MD, PhD
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain

Christine Bestvina, MD
Associate Professor
University of Chicago Medicine
Division of Medicine
Section of Hematology/Oncology
University of Chicago Medicine
Chicago, Illinois

Link to full program:
https://bit.ly/4rhoUuN

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

support@deceraclinical.com (Ibrahim Aldoss MD, Bijal Shah MD) — Fri, 27 Feb 2026 17:25:45 +0000

In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:

CD19-directed CAR T-cell therapies
Next-generation CD19 bispecific antibodies
The evolving role of allogeneic transplant

Presenters:

Ibrahim Aldoss, MD
Associate Professor
Division of Leukemia
Department of Hematology/HCT
City of Hope National Medical Center
Duarte, California

Bijal Shah, MD, MS
Senior Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Link to full program:
https://bit.ly/4cRjiUi

Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer

support@deceraclinical.com (Nilofer Azad MD FASCO, Zev A. Wainberg MD) — Mon, 23 Feb 2026 21:05:00 +0000

In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following:

Optimal KRAS mutation testing
Emerging multiselective RAS inhibitors
Combination strategies

Presenters:

Nilofer Azad, MD, FASCO
Professor of Oncology
Associate Director of Clinical Research
Sidney Kimmel Cancer Center at Johns Hopkins University
Co-Leader, Developmental Therapeutics Clinical Trials Group
Baltimore, Maryland

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director, GI Oncology Program
UCLA School of Medicine
Los Angeles, California

Content based on an online CME program supported by an educational grant from Revolution Medicines, Inc.

Link to full program:
https://bit.ly/4avdRZK

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer

support@deceraclinical.com (Beth Sandy MSN CRNP FAPO, Denise Rouse MS PA-C) — Fri, 20 Feb 2026 17:21:34 +0000

Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients with lung cancer.

Presenters:

Beth Sandy, MSN, CRNP, FAPO
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Denise Rouse, MS, PA-C
Physician Assistant
Thoracic Medical Oncology
Department of Medicine, Section of Hematology/Oncology
The University of Chicago Medicine & Biological Sciences
Chicago, Illinois

Link to full program:
https://bit.ly/4rt1OCl

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Individualized Hemophilia Care With Hemostatic Rebalancing Therapies

support@deceraclinical.com (Angela Weyand MD, Guy Young MD) — Fri, 30 Jan 2026 19:37:21 +0000

In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for patients older than 12 years of age.This podcast explores similarities and differences between the rebalancing agents, such as dosing, necessary lab testing, and safety profiles, that are important to discuss with patients and their caregivers.

Presenters:

Angela Weyand, MD
Associate Professor, Pediatric Hematology Oncology
Co-Director, Combined Hematology/Gynecology Program
Pediatric Medical Director, Hemophilia Treatment Center
University of Michigan Medical School
Ann Arbor, Michigan

Guy Young, MD
Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disease Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET

support@deceraclinical.com (Joan How MD, Pankit Vachhani MD) — Wed, 21 Jan 2026 19:42:08 +0000

In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including:

Personal insights and examples of the process of SDM with patients with PV or ET
How nuances of managing PV/ET influence SDM
Individualizing the process of SDM
Barriers to effective SDM
Educational resources for patients with PV, ET, or MPNs
Working with a team to incorporate SDM into clinical practice

Program faculty:

Joan How, MD
Scientific and Medical Consultant
Clinical Chief of Hematology
Brigham and Women's Faulkner Hospital
Associate Physician
Brigham and Women's Hospital
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Pankit Vachhani, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of Alabama at Birmingham
O’Neal Comprehensive Cancer Center at the UAB
Birmingham, Alabama

Link to obtain CME/CE credit:
https://bit.ly/3ZtxWJm

Link to program page:
https://bit.ly/3YQKlHb

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, Podcasts, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss CELMoD Agents for Treating Multiple Myeloma

Tue, 30 Dec 2025 05:00:00 +0000

In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:

Combination strategies
Adverse event management
Where CELMoD agents may best fit within current and future treatment strategies

Presenters:

Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Orange County
Professor Hematology/HCT
Irvine, California

Niels van de Donk, MD, PhD
Professor of Hematology
Department of Hematology
Amsterdam UMC, Location VUmc
Amsterdam, Netherlands

Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/4qvRwQM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting

support@deceraclinical.com (Rami Komrokji MD) — Tue, 30 Dec 2025 05:00:00 +0000

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:

Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MF
Abstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
Abstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MF
Abstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDS
Abstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDS
Abstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDS

Presenter:

Rami Komrokji, MD

Senior Member, Vice Chair
Section Head – Leukemia and MDS
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, Florida

Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

Link to full program:
https://bit.ly/48Ye45N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Highlights From the 2025 World Conference on Lung Cancer

support@deceraclinical.com (John Heymach MD PhD, Solange Peters MD PhD) — Wed, 24 Dec 2025 13:53:45 +0000

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).

Presenters:

John Heymach, MD, PhD
Chair and Professor
Department of Thoracic/Head and Neck Medical Oncology
Ruth Legett Jones Distinguished Chair
MD Anderson Cancer Center
Houston, Texas

Solange Peters, MD, PhD
Professor and Director of Medical Oncology
Department of Oncology
University Hospital of Lausanne
Lausanne, Switzerland

Content based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Link to full program:
https://bit.ly/3L1eksI

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting

support@deceraclinical.com (Shaji K. Kumar MD) — Tue, 23 Dec 2025 21:46:21 +0000

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:

MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM
RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary disease
CARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogenetics
STEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapy
CAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MM

Presenter:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/4995nFA

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

support@deceraclinical.com (Jeremy S. Abramson MD MMSc) — Fri, 19 Dec 2025 16:05:31 +0000

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:

CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL
BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLL
BRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL
EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FL
STARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCL

Presenter:

Jeremy S. Abramson, MD, MMSc
Professor of Medicine
Harvard Medical School
Director, Center for Lymphoma
Mass General Brigham Cancer Ins
Boston, Massachusetts

Link to full program:
https://bit.ly/4aqMobZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

support@deceraclinical.com (Hanny Al-Samkari MD) — Thu, 18 Dec 2025 14:32:31 +0000

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including:

LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
Abstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapy
Abstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infections
Abstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand disease
Abstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitors

Presenter:
Hanny Al-Samkari, MD
The Peggy S. Blitz Endowed Chair in Hematology/Oncology
Co-Director, Hereditary Hemorrhagic Telangiectasia Center of Excellence
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/48Ye45N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting

support@deceraclinical.com (Amir T. Fathi MD) — Wed, 17 Dec 2025 16:06:00 +0000

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:

Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AML
Abstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AML
Abstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AML
Abstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapy
Abstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CML
Abstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKI

Presenter:
Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/48Ye45N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

support@deceraclinical.com (Benjamin Levy MD FASCO, Alex Spira MD PhD FASCO) — Tue, 18 Nov 2025 22:00:00 +0000

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:

TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan
TROP2 ADCS for patients with EGFR-mutated NSCLC
TIGIT-targeting agents: domvanalimab, rilvegostomig

Presenters:

Benjamin Levy, MD, FASCO
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)
Washington, DC

Alex Spira, MD, PhD, FASCO
Director Clinical Research
Virginia Cancer Specialists
CEO NEXT Oncology Virginia
Fairfax, Virginia

Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.

Link to full program:
https://bit.ly/4qZLR6B

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

support@deceraclinical.com (Rachel Grisham MD, Kathleen N. Moore MD MS FASCO) — Thu, 6 Nov 2025 22:24:23 +0000

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:

Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection
The recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)
Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON

Presenters:
Rachel Grisham, MD
Section Head of Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Director Gynecologic Medical Oncology, MSKCC Westchester
New York, New York

Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

Wed, 5 Nov 2025 18:10:04 +0000

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:

Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
How R-DXd may be incorporated into the treatment paradigm
Other investigational CDH6-targeting ADCs: CUSP06, SIM0505

Presenters:

Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma

Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Reshape Lab Inserm u1290
Université Claude Bernard Lyon Est
Lyon, France

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program:
https://bit.ly/43PXoeP

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care

support@deceraclinical.com (David M. Miller MD PhD FAAD, Vishal Anil Patel MD) — Fri, 31 Oct 2025 13:20:48 +0000

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:

Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab, pembrolizumab, atezolizumab, and nivolumab with or without ipilimumab
Ongoing investigational efforts, including the phase III CLEAR CSCC study of intralesional immunotherapy and radiation-immunotherapy sequencing

Presenters:

David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Massachusetts General Cancer Center
Assistant Professor of Medicine and Dermatology
Harvard Medical School
Boston, Massachusetts

Vishal Anil Patel, MD
Director of Cutaneous Oncology, GW Cancer Center
Director of Dermatologic Surgery, GW Department of Dermatology
Associate Professor of Dermatology & of Medicine (Hematology/Oncology)
George Washington University School of Medicine & Health Sciences
Washington, DC

Link to full program:
https://bit.ly/3JbflO3

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management

Tue, 28 Oct 2025 16:53:52 +0000

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:

The pathogenesis of PNH and the role of complement activation
Landmark therapies such as eculizumab and ravulizumab
Advances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)
Quality-of-life considerations, treatment personalization, and emerging therapies

Presenters:

Carlos M. De Castro, MD
Professor of Medicine, DUMC
Division of Malignant Hematology and Cellular Therapy
Department of Medicine
Duke University
Duke Cancer Institute
Durham, North Carolina

David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath
Consultant Hematologist and Director of Bone Marrow Transplant Program
Professor of Medicine
Division of Hematology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Link to full program:
https://bit.ly/3Jtjqgr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

support@deceraclinical.com (Erin F. Cobain MD, Manali Bhave MD) — Tue, 14 Oct 2025 15:37:11 +0000

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Link to obtain CME/CE credit:
https://bit.ly/46RvtgH

Link to Oncology Breast Cancers with additional educational activities:
https://bit.ly/4h7R3AO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer

support@deceraclinical.com (Erin F. Cobain MD, Manali Bhave MD) — Tue, 14 Oct 2025 14:59:47 +0000

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy for these patients. Supported by an educational grant from Lilly.

Faculty:

Manali Bhave, MD
Medical Director, Phase I Clinical Trials Unit
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Erin F. Cobain, MD
Associate Professor of Internal Medicine
Division of Hematology/Oncology
Breast Oncology Program
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Link to obtain CME/CE credit:
https://bit.ly/4nUJO1O

Link to Oncology Breast Cancers with additional educational activities:
https://bit.ly/4nNGlBY

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options

support@deceraclinical.com (Shubham Pant MD, Amit Mahipal MD MPH) — Mon, 13 Oct 2025 13:54:04 +0000

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:

Brief overview of BTC and GEA
Approved HER2-directed therapies for BTC and GEA and their mechanisms of action
Efficacy and toxicities of the approved agents and optimal management strategies
Key ongoing trials of HER2-directed therapies in BTC and GEA
Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA

Presenters

Amit Mahipal, MD, MPH
Director, Gastrointestinal Medical Oncology Program
Ruth and Donald Goodman Endowed Chair in GI Oncology
Professor of Medicine, Senior Attending Physician
University Hospitals Siedman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Shubham Pant, MD
Professor
Department of Gastrointestinal (GI) Medical Oncology
Department of Investigational Cancer Therapeutics
Director of Clinical Research
Associate Director for Early Phase Drug Development
Sheikh Ahmed Bin Zayed Al Nahyan Center
MD Anderson Cancer Center
Houston, Texas

Link to full program:
https://bit.ly/3KL2ank

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma

support@deceraclinical.com (Christoper Flowers, John Allan) — Thu, 11 Sep 2025 18:59:34 +0000

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymphoma. The overall discussion between these 2 experts includes:

Using bispecific antibodies in clinical practice for relapsed/refractory follicular lymphoma, including an overview of the drugs mosunetuzumab, epcoritamab, and odronextamab
Monitoring and managing CRS and ICANS when prescribing bispecific antibodies to patients with relapsed/refractory follicular lymphoma
Promising ongoing clinical trials with bispecific antibodies for patients with follicular lymphoma, such as EPCORE FL-1 with epcoritamab, OLYMPIA-5 with odronextamab, and SOUNDTRACK-F1 with surovatamig

Presenters:

Dr Christopher Flowers
Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Dr John Allan
Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by Regeneron Pharmaceuticals, Inc.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients

Thu, 4 Sep 2025 17:42:48 +0000

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:

How patients often present with disease-related symptoms
Treatment selection considerations for the first-line and second-line setting
How to approach palliative care discussions with patients
Emerging therapies that are showing promise in this setting

Presenters

Paul E. Oberstein, MD
Associate Professor of Medicine
Section Chief, GI Oncology
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Mark O’Hara, MD
Associate Professor of Medicine
Division of Hematology and Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program:
https://bit.ly/45NdBTx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma

support@deceraclinical.com (Brad Kahl MD, Noopur Raje MD) — Wed, 3 Sep 2025 20:02:09 +0000

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.

Lymphomas
- DLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCT
- FL: Tisa-cel (ELARA), axi-cel (ZUMA-5)
- MZL: Liso-cel (TRANSCEND FL)
- MCL: Real-world outcomes post brexu-cel
- CLL: Liso-cel (TRANSCEND CLL 004)
Multiple Myeloma
- Cilta-cel (CARTITUDE-1)
- Anito-cel (iMMagine-1)
- GC012F
- Arlo-cel
- BMS-986453
- TriPRIL

Presenters:

Brad Kahl, MD
Professor of Medicine
Washington University
St Louis, Missouri

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/3ViR62V

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

Tue, 26 Aug 2025 18:40:00 +0000

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:

Genomic testing options for assessing risk of recurrence
Adjuvant treatment duration and holidays with CDK4/6 inhibitors
Managing renal toxicities, prophylaxis for DVT, and asymptomatic ILD
CDK4/6 inhibitors with inavolisib and fulvestrant

Presenters:
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Heather McArthur, MD, MPH, FASCO
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Joanne Mortimer, MD, FACP, FASCO
Vice Chair, Medical Oncology
Professor, Division of Medical Oncology & Experimental Therapeutics
Associate Director for Education and Training
Baum Family Professor of Women’s Cancers
City of Hope Comprehensive Cancer Center
Duarte, California

Link to full program:
https://bit.ly/4osHLTm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

support@deceraclinical.com (Daniel Morgensztern MD, Jonathan Strosberg MD) — Fri, 15 Aug 2025 17:39:46 +0000

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:

The clinical implications of using DLL3 as a therapeutic target
The impact of emerging DLL3-targeted therapies on evolving treatment paradigms
How to incorporate DLL3-based treatments into clinical practice

Presenters:

Daniel Morgensztern, MD
Professor of Medicine
Clinical Director of Thoracic Oncology
Washington University School of Medicine
St Louis, Missouri

Jonathan Strosberg, MD
Professor
Department of GI Oncology
Moffitt Cancer Center and Research Institute
Tampa, Florida

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program:
https://bit.ly/4mjNPfy

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective

support@deceraclinical.com (Kelly Romo PharmD BCOP, Shawna Kraft PharmD BCOP) — Tue, 12 Aug 2025 14:44:35 +0000

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:

Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations

Presenters:

Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025

support@deceraclinical.com (Max S. Topp MD, Pier Luigi Zinzani MD PhD) — Mon, 28 Jul 2025 18:31:17 +0000

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts:

POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL
ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL
CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL
InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL
SHR2554: Oral EZH2 Inhibitor in R/R PTCL
SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL

Presenters:

Max S. Topp, MD
Head of Hematology and Clinical CAR-T Program Lead
Associated Professor
Medinische Klinik und Poliklinkik II
University of Wurzburg
Wurzburg, Germany

Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Alma Mater Studiorum- University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Link to full program:
https://bit.ly/4obcJPI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting

support@deceraclinical.com (Kevin Kalinsky MD MS FASCO, Sara M. Tolaney MD MPH) — Fri, 25 Jul 2025 16:56:05 +0000

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including:

DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancer
ASCENT-04/KEYNOTE-D19: phase III trial of first-line sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in PD-L1–positive advanced TNBC
SERENA-6: phase III trial of ctDNA-guided switch to camizestrant plus CDK4/6i vs continued AI plus CDK4/6i following ESR1 mutation emergence in HR-positive/HER2-negative advanced breast cancer
INAVO120: OS from phase III study of first-line inavolisib/PBO plus palbociclib plus fulvestrant in PIK3CA-mutated, HR-positive/HER2-negative, endocrine-resistant advanced breast cancer

Presenters:

Kevin Kalinsky, MD, MS, FASCO
Professor of Medicine
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Winship Cancer Institute
Emory University
Atlanta, Georgia

Sara M. Tolaney, MD, MPH
Chief, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

Link to full program:
https://bit.ly/4lFS4BC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC

support@deceraclinical.com (Shipra Gandhi MD MS, Laura Spring MD) — Fri, 25 Jul 2025 13:18:47 +0000

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:

Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancer
Interactive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancer
Outcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs

Program faculty:

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Shipra Gandhi, MD, MS
Associate Professor
Director, Breast Translational Research
Glenn Family Breast Center
Winship Cancer Institute of Emory University
Atlanta, Georgia

Resources:
To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

support@deceraclinical.com (Eytan M. Stein MD, Eunice S. Wang MD) — Thu, 24 Jul 2025 19:16:37 +0000

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.

Presenters:

Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Eunice S. Wang, MD
Chief, Leukemia Service
Professor of Oncology
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Link to full program:
https://bit.ly/4f4an0O

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025

Wed, 23 Jul 2025 18:00:00 +0000

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:

The randomized phase III FLAIR trial
The randomized phase III SEQUOIA trial
The randomized phase III BRUIN CLL-321 trial

Presenters:

James Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
MUSC Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina

Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Link to full program:
https://bit.ly/3H2EcSX

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma

Fri, 18 Jul 2025 19:59:07 +0000

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:

Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC
Overview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab)
Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCC

Program faculty:

Joseph W. Franses, MD, PhD
Assistant Professor of Medicine
Section of Hematology-Oncology
University of Chicago
Chicago, Illinois

Neehar Parikh, MD, MS
Associate Professor
Li Ka Shing Research Professor of Hepatology
Clinical Director of Hepatology
Medical Director, Liver Tumor Program
Division of Gastroenterology & Hepatology
University of Michigan
Ann Arbor, Michigan

Mark Yarchoan, MD
Associate Professor
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland

Resources:
To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies

Fri, 18 Jul 2025 19:57:02 +0000

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 2025.

The Landscape of Frontline Options in HL
Special Considerations for Older Patients
Special Considerations for Pediatric Patients
Future Directions in HL

Presenters:

Jonathan W. Friedberg, MD
Director, Wilmot Cancer Institute
Samuel Durand Professor of Medicine and Oncology
University of Rochester
Rochester, New York

Alex F. Herrera, MD
Chief, Division of Lymphoma
Professor, Department of Hematology and Hematopoietic Cell Transplantation
Medical Director of the City of Hope Clinical Trials Office
Associate Medical Director of the Briskin Center for Clinical Research
City of Hope Medical Center
Duarte, California

Kara M. Kelly, MD
Waldemar J. Kaminski Endowed Chair of Pediatrics
Roswell Park Comprehensive Cancer Center
Division Chief and Professor of Pediatrics
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Buffalo, New York

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to CME: Claim Credit
https://bit.ly/3TQ0M45

Link to full program:
https://bit.ly/4eV8AuW

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss CELMoDs in Myeloma

Tue, 15 Jul 2025 18:57:04 +0000

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including:

Mechanistic differences between CELMoDs and IMiDs
Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma
The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma

Presenters:

Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Myeloma
Executive Director of Hematology
City of Hope Orange County
Professor of Hematology/HCT
City of Hope Cancer Center
Irvine, California

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/3IwbslQ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Thu, 29 May 2025 18:25:57 +0000

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:

Key Comorbidities in Patients with HR+/HER2- MBC
Impact of Polypharmacy
Role of APPs in Comprehensive Care
Role of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBC
Utility of RWE data
Communicating Treatment Options With Patients and Caregivers
Understanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of Life

Link to full program:
https://bit.ly/4jCQe38

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications

Fri, 16 May 2025 19:24:39 +0000

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.

Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, neuropathy, and cytopenia across ADCs
On-Target vs Off-Target Effects: How linker design, payload type, and drug-to-antibody ratio (DAR) contribute to toxicity
Combination Therapy Considerations: Challenges in combining ADCs with immunotherapy or chemotherapy due to overlapping toxicities and tolerability concerns

Presenters:

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Alexandra Leary, MD, PhD
President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Link to full program:
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies

Mon, 5 May 2025 20:45:00 +0000

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers.

Mechanisms of action of ADCs: how ADCs selectively deliver potent chemotherapy to tumor cells
Clinical data across tumor types: highlights from recent trials with trastuzumab deruxtecan and exploration of emerging data on agents such as disitamab vedotin
Challenges and future directions:key considerations for combining HER2-targeted ADCs with immunotherapy or chemotherapy, and sequencing ADC therapies

Presenters:

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Alexandra Leary, MD, PhD
President, GINECO Group
Co-Director, Department of Medical Oncology
Medical Oncologist Gynecology
Team Leader, Gynecologic Translational Research Lab, INSERM u981
Institut Gustave Roussy
Villejuif, France

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Link to full program:
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

support@deceraclinical.com (Lauren Byers MD, Christine L. Hann MD PhD) — Thu, 24 Apr 2025 04:00:00 +0000

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including:

Rationale for targeting B7-H3
Overview of the structure of antibody-drug conjugates (ADCs)
Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLC
Data from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLC
An overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLC
Early phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093

Program faculty:

Lauren Byers, MD
Professor and Thoracic Section Chief
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, Texas

Christine L. Hann, MD, PhD
Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Johns Hopkins University School of Medicine
Baltimore, Maryland

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Mon, 21 Apr 2025 21:55:28 +0000

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies.

HER2 Testing in Advanced Cancers: Recommendations for when and how to test for HER2 in advanced cancers and how these tests guide therapy selection
Variability in HER2 Expression Across Tumor Types: Insights into the heterogeneity of HER2 expression and amplification in different cancers
Challenges in Standardizing HER2 Testing: The complexities of scoring and testing HER2 in different cancers and institutions, and the need for better harmonization of guidelines and approaches

Presenters:
Zev A. Wainberg, MD
Professor of Medicine and Surgery
Co-Director of GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Catherine Fahey, MD, PhD
Assistant Professor
Division of Oncology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Link to full program:
https://bit.ly/42iEDjV

To claim credit for listening to this episode, please visit the podcast online at the link above.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

support@deceraclinical.com (Stephanie L. Graff MD FACP FASCO, Laura Spring MD) — Tue, 25 Mar 2025 22:17:17 +0000

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:

Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies
Treatment sequencing and preferred treatment options in patients with brain metastases
Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer
Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial

Program faculty:

Stephanie L. Graff, MD, FACP, FASCO
Director of Breast Oncology, Brown University Health
Co-Lead, Breast Cancer Translational Disease Research Group
Legorreta Cancer Center at Brown University
Associate Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Resources:
To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

Thu, 20 Feb 2025 17:12:03 +0000

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat patients with early and metastatic hormone receptor (HR)–positive/HER2-negative breast cancer from a live program held in January 2025. Key clinical pearls include:

Adjuvant treatment selection recommendations for patients with HR-positive/HER2-negative early breast cancer based on disease and patient characteristics as well as the latest data and guidelines presented by Dr. Gradishar
Therapeutic strategies for patients diagnosed with HR-positive/HER2-negative metastatic breast cancer (MBC) presented by Dr. Abraham
Addressing challenges related to CDK4/6 inhibitor adherence and adverse event mitigation presented by Dr. Spring

Presenters:

Jame Abraham, MD, FACP
Enterprise Chair and Professor of Medicine
Department of Hematology and Medical Oncology
Cleveland Clinic
Cleveland, Ohio

William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Laura Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Link to full program including downloadable slides and on-demand webcasts:
https://bit.ly/4b5GFqq

To claim credit for listening to this episode, please visit the podcast online at the link above.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

support@deceraclinical.com (Shaji K. Kumar MD) — Mon, 10 Feb 2025 05:00:00 +0000

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:

Early results with teclistamab combined with anti-CD38 therapy
Real-world data with teclistamab including its use after other BCMA-targeted therapies
Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy

Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/40bjFCZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Thu, 9 Jan 2025 05:00:00 +0000

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:

Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast cancer
Current guideline recommendations for when to pursue ESR1 mutation testing mutations in patients with HR-positive/HER2-negative advanced breast cancer
Choice and sequencing of next line of systemic therapy for ESR1-mutated advanced breast cancer based on tumor molecular alterations
Overview of class-related and unique adverse events with approved and emerging oral SERDS
Expert recommendations for the management of oral SERDs-related adverse events

Program faculty:

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

support@deceraclinical.com (Caitlin Costello MD) — Tue, 22 Oct 2024 19:24:42 +0000

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:

3 bispecific antibodies approved for the treatment of R/R MM that target BCMA or GPRC5D
The role of bispecific antibodies in R/R MM
Safety considerations for patients while receiving a bispecific antibody
Emerging data and clinical trials with bispecific antibodies
Key clinical pearls for optimal use of bispecific antibodies

Presenter:

Caitlin Costello, MD
Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Link to full program:
https://bit.ly/40bjFCZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

support@deceraclinical.com (Thor R. Halfdanarson MD, Jonathan Strosberg MD) — Wed, 16 Oct 2024 15:43:00 +0000

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:

The diagnosis and typical presenting symptoms of GEP-NETs
Findings from recent key phase III studies including NETTER-2 and CABINET
Recommendations for treatment sequencing
Notable clinical pearls regarding GEP-NET therapies
Current guidelines for GEP-NET care and monitoring

Presenters:

Thor R. Halfdanarson, MD
Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota

Jonathan Strosberg
Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida

Link to full program:
https://bit.ly/3Y0JWBa

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

support@deceraclinical.com (Ana Oaknin MD PhD, Alexandra Leary MD PhD) — Tue, 1 Oct 2024 13:17:41 +0000

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:

Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian Cancer
ATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian Cancer
Phase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα Expression
Phase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual Disease
Phase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer

Program faculty:

Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Alexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab,
Institut Gustave Roussy
Paris, France

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

support@deceraclinical.com (Matthew S. Davids MD MMSc, Lindsey Roeker MD) — Mon, 30 Sep 2024 15:11:45 +0000

In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

Contemporary treatment paradigms for patients with CLL
Safety and efficacy of current regimens
Molecular testing, including when and how to test for BTK inhibitor resistance
Considering BTK inhibitor resistance when sequencing therapy

Program faculty:

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Lindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

support@deceraclinical.com (Jessica J. Lin MD, Alice T. Shaw MD PhD) — Fri, 6 Sep 2024 15:34:33 +0000

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

support@deceraclinical.com (Jessica J. Lin MD, Alice T. Shaw MD PhD) — Thu, 5 Sep 2024 17:29:21 +0000

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
Long-term safety observations for crizotinib and entrectinib
CNS activity of entrectinib and repotrectinib in patients with brain metastases
Repotrectinib activity in ROS1-TKI resistance mutations

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

ROS1-Alterations and Molecular Testing in Advanced NSCLC

support@deceraclinical.com (Jessica J. Lin MD, Alice T. Shaw MD PhD) — Wed, 28 Aug 2024 19:44:44 +0000

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

ROS1-gene fusions in advanced lung cancer
ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
Advantages of RNA- vs DNA-based next-generation sequencing

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

support@deceraclinical.com (Floor J. Backes MD, Angeles Alvarez Secord MD MHSc) — Mon, 5 Aug 2024 04:00:00 +0000

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:

RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancer
RUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancer
Survival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancer
DUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancer
Long-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatin
Subgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancer
Subgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancer
Phase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapy
innovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancer
Randomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancer

Program faculty:

Floor J. Backes, MD
Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Mon, 22 Jul 2024 14:11:41 +0000

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.

Presenters:
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Sarah Sammons, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/46hLGcM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Current Clinical Practice and NCCN Guidelines for CLL/SLL

Thu, 18 Jul 2024 20:07:12 +0000

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:

Prognostic variables when deciding between regimens
Role of MRD in CLL
Results from the phase II CAPTIVATE trial
Choosing among the available covalent BTK inhibitors
Preferred partner anti-CD20 antibody in CLL/SLL
Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
Use of CAR T-cell therapy in CLL/SLL

Presenters:

Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.

Link to full program:
https://bit.ly/3LzA2As

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

support@deceraclinical.com (Brady L. Stein MD MHS) — Fri, 12 Jul 2024 04:00:00 +0000

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:

Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib

Program faculty:

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

support@deceraclinical.com (Julio C. Chavez MD MS, Alan Skarbnik MD) — Thu, 11 Jul 2024 15:58:55 +0000

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:

Rationale for targeting CELMoDs in NHL
Mechanism of action of CELMoDs
Key studies and available efficacy and safety data with investigational CELMoDs in NHL
Key ongoing clinical trials of CELMoDs in NHL
Strategies to boost NHL clinical trial diversity among underserved communities

Presenters:

Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Alan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/45YXoZI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Tue, 9 Jul 2024 19:28:21 +0000

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include:

Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancer
Factors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expression
Determining the need for adjuvant chemotherapy and selection of chemotherapy agents
Selection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapy
Potential use of preoperative CDK4/6 inhibitors
Sequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutation
Overview of first-line therapy for advanced HR+/HER2 breast cancer
Expert opinion on selection of first-line therapy and factors to consider
Selection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trial

Presenters:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Sara A. Hurvitz, MD, FACP
Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/3XZKp8f

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Congress to Clinic: Expert Takeaways on Emerging Data for AML

support@deceraclinical.com (Eunice S. Wang MD, Courtney DiNardo MD MSCE) — Mon, 8 Jul 2024 04:00:00 +0000

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:

Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML
Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AML
A retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML
Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapy
Final 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML
Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 study
First-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase
A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1

Program faculty:

Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Courtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Resources:
To download the slides associated with this podcast discussion, please visit the program page:
https://bit.ly/4bvJGij

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Congress to Clinic: Expert Takeaways on Emerging Data for MDS

Fri, 5 Jul 2024 14:22:44 +0000

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:

COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDS
Real-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practice
Phase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDS
Phase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS
Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS
Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis

Program faculty:

Courtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

Tue, 14 May 2024 04:00:00 +0000

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer.

Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients.

Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.

Presenters:

Manali Bhave, MD
Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Annalise Labatut, PharmD, BCOP
Oncology Clinical Pharmacy Specialist – Breast Oncology
Emory Healthcare/Winship Cancer Institute
Atlanta, Georgia

Jamie L. Carroll, CNP, APRN, MSN
Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Link to the full program:
https://bit.ly/3UT5Be8

Claim CME Credit:
https://bit.ly/4dBuxhx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Tue, 7 May 2024 16:44:35 +0000

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:

Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors
Considerations in therapy selection for previously treated CLL
Novel strategies for treating CLL

Presenters:

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Deborah Stephens, DO
Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Content based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.

Link to full program including downloadable slides:
https://bit.ly/49YxtSq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer

support@deceraclinical.com (Heather H. Cheng MD PhD, Colin C. Pritchard MD PhD) — Thu, 28 Mar 2024 16:28:00 +0000

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:

Rationale for targeting PARP in prostate cancer with ARI combinations
Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
Tips for optimal coordination between pathology and medical oncology

Presenters:

Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington

Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington

Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.

Link to full program:
https://bit.ly/3PFagxb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer

support@deceraclinical.com (Sara M. Tolaney MD MPH, Melinda Telli MD) — Mon, 18 Mar 2024 14:38:29 +0000

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:

Challenges with the pathologic testing for HER2-low expression
Optimal treatment of patients with HER2-low advanced breast cancer
Role of TROP-2–targeted therapies
Management of ADC-associated adverse events to optimize treatment outcomes
ADCs on the horizon for patients with advanced breast cancer

Presenters:

Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Melinda Telli, MD
Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Link to full program:
https://bit.ly/49WxRBM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Current Considerations for Adverse Event Management With HER3-Directed Agents

support@deceraclinical.com (Rebecca S. Heist MD MPH, Helena Yu MD) — Tue, 26 Dec 2023 19:43:45 +0000

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer.

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Unpacking the Potential of HER3-Targeted Therapy in NSCLC

support@deceraclinical.com (Helena Yu MD, Rebecca S. Heist MD MPH) — Tue, 26 Dec 2023 19:43:22 +0000

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:

Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
The HER2xHER3 bispecific antibody zenocutuzumab
The HER3-targeted antibody–drug conjugate SHR-A2009

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

support@deceraclinical.com (Helena Yu MD, Rebecca S. Heist MD MPH) — Tue, 26 Dec 2023 05:00:00 +0000

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs.

Presenters in this series include:

Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Mon, 4 Dec 2023 13:56:25 +0000

In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including:

Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer.
Phase III ENGOT-EN6/GOG-3031/RUBY trial of carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or placebo maintenance for 3 years in patients with primary advanced or recurrent endometrial cancer.
Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer.
Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of carboplatin and paclitaxel vs durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer.
An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE).
Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy vs placebo plus chemoradiation in patients with high-risk locally advanced cervical cancer.
Phase III ICON8B study comparing carboplatin, paclitaxel, and bevacizumab every 3 weeks vs dose-dense weekly paclitaxel plus bevacizumab every 3 weeks in newly diagnosed high-risk epithelial ovarian cancer, either stage III (with residual disease or requiring new adjuvant chemotherapy) or stage IV.

Presenters:

Brian Slomovitz, MD, MS, FACOG
Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor
Obsterics and Gynecology
Florida International University
Member, Board of Directors
GOG Foundation
Uterine Cancer Lead
GOG Partners
Miami, Florida

Keiichi Fujiwara, MD, PhD
Professor of Gynecologic Oncology
Saitama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan
This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis

support@deceraclinical.com (Jacqueline S Garcia MD) — Thu, 30 Nov 2023 14:09:57 +0000

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

Navitoclax (BCL-XL/BCL-2 inhibitor)
Pelabresib (BET inhibitor)
Imetelstat (telomerase inhibitor)
Luspatercept (erythroid maturation agent)
Additional strategies

Presenter:

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Year in Review and a Look to the Future: BTKi in CLL and MCL

support@deceraclinical.com (ana marin-niebla md phd, stephan stilgenbauer md) — Mon, 20 Nov 2023 05:00:00 +0000

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:

SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
BRUIN: Pirtobrutinib for Previously Treated MCL
GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
BRUIN: Pirtobrutinib for Previously Treated CLL

Presenters:

Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain

Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany

Link to full program:
https://bit.ly/3MNaUri

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

support@deceraclinical.com (Ana Oaknin MD PhD, Isabelle Ray-Coquard MD PhD) — Fri, 17 Nov 2023 19:36:09 +0000

In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including:

Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer
Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer
First results from a phase II biomarker-directed platform study with assigned treatments for patients with measurable persistent or recurrent platinum-resistant epithelial ovarian cancer based on tumor-specific molecular alterations (ENGOT-GYN/GOG-3051/BOUQUET)
Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer
An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE)
Primary results from the global, randomized phase III BEATcc trial of atezolizumab plus platinum-based chemotherapy + bevacizumab as frontline treatment in patients with persistent, recurrent, or metastatic cervical cancer
Interim analysis results from the global, randomized, open-label phase III innovaTV 301 study of tisotumab vedotin vs investigator’s choice of chemotherapy in second-line or third-line recurrent/metastatic cervical cancer

Presenters:

Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Laboratories RESHAPE
Université Claude Bernard Lyon Est
Lyon, France

This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer

Tue, 7 Nov 2023 05:00:00 +0000

In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous targeted therapies and parallels to other approved antibody–drug conjugates. Their conversation covers clinical trial data from:

Phase I/II study of patritumab deruxtecan in HR-positive/HER2-negative or triple-negative metastatic breast cancer, published by Krop and colleagues in the Journal of Clinical Oncology
BRE-354: A phase II study of patritumab deruxtecan in several subtypes of previously treated advanced/metastatic breast cancer, presented at ASCO 2023
ICARUS-Breast01: A phase II study of patritumab deruxtecan in patients with HR-positive/HER2-negative or HER2-low advanced breast cancer, presented at the ESMO Breast Cancer Congress 2023
SOLTI-TOT-HER3: A window-of-opportunity study of neoadjuvant patritumab deruxtecan for treatment-naive HER2-negative early stage breast cancer, presented at the ESMO Breast Cancer Congress 2023
HERTHENA-Lung01: A phase II study of patritumab deruxtecan in in patients with EGFR-mutated NSCLC after treatment with osimertinib and platinum-based chemotherapy, presented at the World Conference on Lung Cancer 2023
HERTHENA-Lung02: An ongoing phase III study of patritumab deruxtecan vs platinum-based chemotherapy after osimertinib for the treatment of EGFR-mutated NSCLC
eNRGy: A phase I/II study of the bispecific HER2 x HER3 antibody zenocutuzumab in multiple solid tumor types with NRG1 gene fusion, presented at ASCO 2022
DESTINY-Breast04: A phase III study of trastuzumab deruxtecan for the treatment of patients with HER2-low metastatic breast cancer, published by Modi and colleagues in the New England Journal of Medicine
DAISY: A phase II trial of trastuzumab deruxtecan for the treatment of breast cancer with variable levels of HER2 expression including HER2-low and HER2-zero, published by Mosele and colleagues in Nature Medicine

Presenters:

Aakash Desai, MD
Affiliation awaiting contract

Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Paolo Tarantino, MD
Advanced Research Fellow
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Content based on an online CME program supported by an independent educational grant from Daiichi Sankyo, Inc.

Link to full program: https://bit.ly/45UYsw3

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving Care for Black Patients With Endometrial Cancer

Mon, 6 Nov 2023 17:21:08 +0000

In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include:

Data on racial disparities in EC survival
Importance of listening to Black patients to better diagnose EC
Financial and practical considerations regarding care
How to help empower Black patients in shared decision-making with their care team

Presenters:

Leslie R. Boyd, MD
Associate Professor
Department of Obstetrics and Gynecology at NYU Grossman School of Medicine
Director of Division of Gynecologic Oncology
Vice Chair of Gynecology
Department of Obstetrics and Gynecology
Laura and Isaac Perlmutter Cancer Center
New York University Langone Health
New York, New York

Adrienne Moore, RT
President and Board Member
Endometrial Cancer Action Network for African-Americans
Director of Peer Support, SISTER Study
Research Coordinator, Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Washington School of Medicine
Seattle, Washington

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

support@deceraclinical.com (Alexandra Leary MD PhD, Domenica Lorusso MD PhD) — Fri, 13 Oct 2023 04:00:00 +0000

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including:

Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/Recurrent Endometrial Cancer
Global, Open-Label, Phase I/IIa of HER2-Targeting ADC (DB-1303) in Recurrent/Metastatic Endometrial Cancer
Phase III From KEYNOTE-826: Bevacizumab Subgroup Analysis Based on Protocol Specified Final Overall Survival Results
Phase III ICON8B: Weekly DD-CT + Bev vs Q3W CT + Bev as First Line in High-Risk Epithelial Ovarian Cancer
HRD Testing on Cell-Free Tumor DNA From Peritoneal Fluid of Patients With Newly-Diagnosed Epithelial Ovarian Cancer

Presenters:

Alexandra Leary, MD, PhD
Co Director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab, and Seagen.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023

support@deceraclinical.com (Catherine C Coombs MD MS, Toby Eyre MBChB MD) — Wed, 4 Oct 2023 15:33:30 +0000

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL
Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL
BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
ViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for relapsed/refractory and treatment-naive MCL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023

support@deceraclinical.com (Catherine C. Coombs MD MS, Toby Eyre MBChB MD) — Thu, 17 Aug 2023 20:20:17 +0000

In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of:

Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL
BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023

support@deceraclinical.com (Catherine C. Coombs MD MS, Toby Eyre MBChB MD) — Fri, 28 Jul 2023 04:00:00 +0000

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers

support@deceraclinical.com (Kathleen Moore MD, Nicoletta Colombo MD PhD) — Thu, 22 Jun 2023 13:45:43 +0000

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:

ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICR
CCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer
Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer
DUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration
MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator’s choice of CT in platinum-resistant ovarian cancer with high expression of FRα
Patient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancer

Presenters:
Kathleen Moore, MD, MS
Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Nicoletta Colombo, MD, PhD
Associate Professor of Obstetrics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:

bit.ly/43Q5CBI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers

Thu, 4 May 2023 11:25:27 +0000

In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:

NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancer
ENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab plus standard-of-care chemotherapy in primary advanced or recurrent endometrial cancer
Phase I NRG-GY017 study of priming-dose atezolizumab before or concurrently with chemoradiotherapy in locally advanced high-risk cervical cancer
Randomized phase II study of chemoradiation plus pembrolizumab immunotherapy in locally advanced cervical cancer
GOG 3026: phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous ovarian cancer

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Linda Duska, MD, MPH
Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc.

Link to full program: bit.ly/424E3Uq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma

Wed, 26 Apr 2023 13:34:14 +0000

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of:

Considerations with administration, including access challenges
Sequencing Therapies
Future developments with BCMA-targeted therapies

Presenters:

Suzanne Lentzsch, MD, PhD
Professor of Medicine
Division of Hematology/Oncology
Director, Multiple Myeloma and Amyloidosis Program
Columbia University Medical Center
New York, New York

Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor
Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation
HonorHealth Research Institute
Scottsdale, Arizona

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.

Link to full program: bit.ly/41YEOO6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts

support@deceraclinical.com (Decera Clinical Education) — Tue, 11 Apr 2023 04:00:00 +0000

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:

Overall approach to treatment
Use of JAK inhibitors for treating myelofibrosis
Treating patients with low platelets
Defining JAK inhibitor failure
Unmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches

Presenters:

John Mascarenhas, MD
Professor of Medicine

Icahn School of Medicine at Mount Sinai

Director, Adult Leukemia Program

Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute

New York, New York

Ruben A. Mesa, MD, FACP
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Enterprise Senior Vice President, Atrium Health

President, Enterprise Cancer Service Line

Vice Dean for Cancer Programs, Wake Forest University School of Medicine

Professor of Medicine, Wake Forest University School of Medicine

Winston-Salem, North Carolina

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

BRCA Testing and Adjuvant Therapy in Early Breast Cancer: Experiences and Challenges

support@deceraclinical.com (Decera Clinical Education) — Wed, 5 Apr 2023 04:00:00 +0000

In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of:

Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice
The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients
Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them
Administration of adjuvant olaparib with other available adjuvant systemic therapies
Tolerability of single-agent PARP inhibitors

Presenters:

Banu Arun, MD
Professor, Breast Medical Oncology
Director, Clinical Cancer Genetics

University of Texas MD Anderson Cancer Center

Houston, Texas

Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Director, PGY2 Oncology Residency Program

UK HealthCare

Assistant Adjunct Professor

UK College of Pharmacy

Lexington, Kentucky

Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
Nurse Practitioner
Breast Oncology

Texas Oncology Baylor Sammons Cancer Center

Dallas, Texas

Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp.

Link to full program:
https://bit.ly/42VeUMM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers

support@deceraclinical.com (Samuel Klempner MD, Gregory Botta MD PhD) — Tue, 28 Mar 2023 17:13:52 +0000

In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:

Expression patterns and function of the claudin family of proteins in normal gastric tissues
Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology
Prognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancers
Laboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selection
Future directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructs

Presenters:

Samuel Klempner, MD
Associate Professor
Department of Medicine
Division of Hematology-Oncology
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts

Gregory Botta, MD, PhD
Clinical Professor of Medicine
Department of Medicine
Division of Hematology & Oncology
University of California San Diego
La Jolla, California

Content for this program was supported by educational grants from Astellas and Bristol Myers Squibb.

Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):
bit.ly/3lQxPrq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts

support@deceraclinical.com (Andrew Kuykendall MD, Prithviraj Bose MD) — Thu, 23 Feb 2023 21:30:00 +0000

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia.

The topics covered include:

When to use cytoreduction therapies and which therapies to use in low-risk patients
Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports
Experts’ thoughts on therapy options in higher-risk patients

Presenters:

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew Kuykendall, MD
Assistant Professor
Department of Oncologic Sciences
University of South Florida
Assistant Member
Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
bit.ly/3XF3cSF

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia

Mon, 20 Feb 2023 21:20:00 +0000

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.

Topics discussed include:

Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase
Indirect methods for measuring asparaginase activity
Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis
Considerations for use of asparaginase in special populations (eg, high BMI, older age)

Presenters:

Program Director
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Emily Curran, MD
Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow, MD, DMSci
Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.

Link to full program:
http://bit.ly/3YXkLyj

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes

Fri, 17 Feb 2023 17:00:00 +0000

In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:

Practical use of the Molecular International Prognostic Scoring System
Mutational targets and other treatments in ongoing clinical trials
Prophylaxis with venetoclax therapy
Best practices for bone marrow transplant, including induction and salvage regimens
Treatment options for hypoplastic myelodysplastic syndromes

Presenters:
Rami Komrokji, MD
Professor
Department of Oncologic Sciences
University of South Florida
Vice Chair
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

María Díez Campelo, MD, PhD
Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain

Amer Zeidan, MBBS, MHS
Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
http://bit.ly/3YXgKK3

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Answer Questions on the Management of Patients With T-Cell Lymphomas

Fri, 17 Feb 2023 17:00:00 +0000

In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including:

Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomas
Strategies with JAK inhibition and epigenetic agents
Allogeneic transplantation in cutaneous T-cell lymphoma

Presenters:
Steven M. Horwitz MD
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York

Pamela B. Allen, MD, MSc
Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Kerry Savage MD, MSc
Professor of Medicine
University of British Columbia
Medical Oncologist
Division of Medical Oncology
BC Cancer
Vancouver, British Columbia, Canada

Content for this program was supported by educational grants from Daiichi Sankyo; Kyowa Kirin, Inc.; and Seagen Inc.

Link to the full program, including downloadable slides, expert commentary, and an on-demand webcast:
bit.ly/3ItqEOd

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Individualizing Care for Patients With Triple-Negative Breast Cancer

support@deceraclinical.com (Mark Pegram MD, Sara Tolaney MD MPH) — Wed, 18 Jan 2023 21:30:00 +0000

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:

Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC
Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC
Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC
Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC
Role of PARP inhibitors in the treatment of TNBC

Presenters:

Mark Pegram, MD
Professor
Medical Oncology
Stanford University
Palo Alto, California

Sara Tolaney, MD, MPH
Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Content based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc.

Link to full program:
http://bit.ly/3iQzDz5

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Contemporary Approaches to Treating Polycythemia Vera: A Conversation Between Experts

support@deceraclinical.com (Raajit Rampal MD PhD, Brady Stein MD MHS) — Wed, 11 Jan 2023 21:30:00 +0000

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:

Patient presentation and goals of frontline therapy
Considerations for second-line therapy in the setting of treatment intolerance
Experts’ thoughts on the potential of early intervention to alter disease progression

Presenters:

Raajit Rampal, MD, PhD
Associate Member
Associate Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3X3x6jX

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HCC Surveillance: Challenges and Opportunities

support@deceraclinical.com (David E. Kaplan MD MSc, Tamar Taddei MD) — Tue, 3 Jan 2023 21:30:00 +0000

In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance.

Presenters:

David E. Kaplan, MD, MSc
Associate Professor
Perelman School of Medicine
Chief, Hepatology Section
Division of Gastroenterology and Hepatology
University of Pennsylvania
Director of Hepatology
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Tamar Taddei, MD
Professor
Section of Digestive Diseases
Department of Internal Medicine
Yale School of Medicine
Chief, GI Section
VA Connecticut Healthcare System
West Haven, Connecticut

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

support@deceraclinical.com (Zoe Lanham) — Tue, 13 Dec 2022 22:10:00 +0000

In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience.

Presenter:

Zoe Lanham
Patient

Link to full program:
https://bit.ly/3Fukjzk

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Transgender Cancer Experience: A Conversation Between an Oncologist and a Transmasculine Individual on Navigating the Healthcare System

support@deceraclinical.com (Yee Won Chong, Norma Steiner MD) — Tue, 29 Nov 2022 21:30:00 +0000

In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include:

4 aspects of transgender care: emotional, social, medical, legal
Getting language right and how to gracefully recover from fumbles
Sensitively approaching ongoing cancer care in transmasculine and transfeminine individuals
Handling billing and charting challenges when caring for transgender patients
Ideas for institutional change to improve healthcare for transgender individuals

Presenters:

Yee Won Chong
Co-filmmaker, Trans Dudes with Lady Cancer
Senior Fellow, Racial Equity
Western States Center
Equity, Diversity, and Inclusion Strategist and Consultant
Portland, Oregon

Norma Steiner, MD
Gynecological Oncologist
Northwest Permanente
Portland, Oregon

Link to full program:
http://bit.ly/3Ugz0LR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers

support@deceraclinical.com (Isabelle Ray-Coquard MD PhD, Ignace Vergote MD PhD) — Tue, 29 Nov 2022 21:30:00 +0000

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:

• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer

• Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test

• Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial

• Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer

Presenters:

Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven
Leuven, Belgium

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions

support@deceraclinical.com (Farrukh T Awan MD, Nicole Lamanna MD) — Wed, 9 Nov 2022 21:30:00 +0000

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:

Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
Approval of ibrutinib/venetoclax combination therapy for patients with CLL
Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor

Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting

support@deceraclinical.com (Christopher R. Flowers MD MS, Kami Maddocks MD) — Fri, 28 Oct 2022 20:30:00 +0000

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:

GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia
BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)

Presenters:

Christopher R. Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Kami Maddocks, MD
Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting

Mon, 24 Oct 2022 20:30:00 +0000

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:

Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer
Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer
Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer
Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix

Presenters:

Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist and Research Lead
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape

Mon, 24 Oct 2022 20:30:00 +0000

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:

How to sequence currently available therapies after relapse
Challenges with using BCMA-targeted agents in clinical practice
Experts’ thoughts on the potential approval of bispecific agents

Presenters include:

Paul G. Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts

Natalie S. Callander, MD
Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director
Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.

Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3Fc7eMK

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer

support@deceraclinical.com (Domenica Lorusso MD PhD, Alexandra Leary MD PhD) — Tue, 4 Oct 2022 20:30:00 +0000

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:

Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo
Phase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced ovarian cancer
Phase III ATHENA-MONO: outcomes by disease subgroups receiving rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer
Phase III ARIEL4: OS outcomes following treatment with rucaparib vs chemotherapy in patients with relapsed advanced ovarian cancer and a deleterious BRCA1/2 mutation

Presenters:

Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions

support@deceraclinical.com (Ryan Gentzler MD MS, Jonathan Riess MD MS) — Wed, 28 Sep 2022 16:10:00 +0000

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:

• Identifying patients who may benefit the most from adjuvant osimertinib

• Testing for EGFR mutations in early-stage NSCLC

• Critical importance of getting molecular test results before starting immunotherapy

• Monitoring cardiac toxicity in patients receiving osimertinib

• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib

Presenters:

Ryan D. Gentzler, MD, MS
Associate Professor
Division of Hematology/Oncology
Department of Medicine
University of Virginia
Thoracic Medical Oncologist
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia

Jonathan Riess, MD, MS
Associate Professor
Department of Internal Medicine/Hematology-Oncology
University of California, Davis
Medical Director, Thoracic Oncology
University of California, Davis Comprehensive Cancer Center
Sacramento, California

Link to full program:
https://bit.ly/3DZGzSO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022

support@deceraclinical.com (Julie M Vose MD MBA, Matthew S Davids MD MMSc) — Tue, 30 Aug 2022 17:40:00 +0000

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)
MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL
BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)
BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL
BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL

Presenters:

Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to full program:
https://bit.ly/3OQ6634

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management

support@deceraclinical.com (Heinz-Josef Klumpen MD PhD, Chris Verslype MD PhD) — Mon, 22 Aug 2022 20:30:00 +0000

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:

Factors to consider before selecting frontline immunotherapy
Role of TKIs in the frontline
Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy
Real-world evidence on frontline immunotherapy/VEGF combination therapy
Factors to consider when selecting second-line therapy including the role of TKIs and planning for multiple lines of therapy

Presenters:

Heinz-Josef Klumpen, MD, PhD
Staff Specialist, Medical Oncologist
Department of Medical Oncology
Amsterdam UMC
Amsterdam, The Netherlands

Chris Verslype, MD, PhD
Professor
Clinical Digestive Oncology
KULeuven
Head of Clinic
Hepatology
Digestive Oncology
U.Z. Leuven
Leuven, Belgium

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

HER2-Positive Breast Cancer: Current Approaches for Quality Care

support@deceraclinical.com (Erika P Hamilton MD, Komal Jhaveri MD) — Thu, 28 Jul 2022 16:40:00 +0000

In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes:

Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and risk
Sequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central nervous system metastases
Managing common adverse events associated with HER2-targeted therapy

Presenters:

Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Drug Development Unit
Sarah Cannon Research Institute
Investigator
Tennessee Oncology
Nashville, Tennessee

Komal Jhaveri, MD
Assistant Professor of Medicine
Weill Cornell Medical College
Associate Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Follow along with Podcast Pearls slideset:
https://bit.ly/3eMqxB8

See full program:
https://bit.ly/3oBdd45

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022

support@deceraclinical.com (Othman Al-Sawaf MD, Lydia Scarfo MD) — Thu, 21 Jul 2022 20:05:00 +0000

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL

Presenters:

Othman Al-Sawaf, MD
Faculty of Medicine
University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne
Düsseldorf, Germany
Visiting Scientist
The Francis Crick Institute
UCL Cancer Institute, University College London
London, United Kingdom

Lydia Scarfò, MD
Laboratory of B-Cell Neoplasia, Division of Experimental Oncology
Strategic Research Program on CLL
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy

Link to full program:
https://bit.ly/3OQ6634

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

support@deceraclinical.com (Brad Kahl MD, Anthony Mato MD MSCE) — Wed, 6 Jul 2022 20:00:00 +0000

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:

The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL
3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphoma
Phase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL or CLL

Presenters:

Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

See full program:
https://bit.ly/3OQ6634

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

support@deceraclinical.com (Jubilee Brown MD, Elisabeth Diver MD) — Thu, 30 Jun 2022 15:25:00 +0000

In this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and cervical cancers regarding:
Subgroup analyses from KEYNOTE-826 evaluating pembrolizumab in combination with chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer

Preliminary subgroup analyses from phase III ENGOT-EN5/GOG-3055 SIENDO trial of selinexor vs placebo maintenance in recurrent endometrial cancer
Updated analyses from phase I GARNET trial of dostarlimab in dMMR/MSI-H and pMMR/MSS advanced/recurrent endometrial cancer (cohorts A1 and A2)
EndoBARR trial of atezolizumab, bevacizumab, and rucaparib in previously treated recurrent and progressive endometrial cancer
Phase III ATHENA-MONO trial of first-line rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with advanced ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Elisabeth Diver, MD
Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3ufB8Js

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Thu, 19 May 2022 20:00:00 +0000

In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:

Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancer
Final OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm platinum-sensitive relapsed ovarian cancer
Results from the phase III SORAYA trial of mirvetuximab soravtansine, an FRα-targeting ADC with a potent tubulin-targeting maytansinoid (DM4) delivered to tumor cells, in patients with platinum-resistant ovarian cancer who had recurrence within 6 months after last platinum dose and had 1-3 prior treatments
Results from the randomized, double-blind, placebo-controlled phase III trial of selinexor vs placebo as maintenance in patients with stage IV endometrial cancer who had a PR/CR on ≥12 weeks of first-line taxane/carboplatin
The results from a cost-effectiveness analysis for the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Angeles Alvarez Secord, MD, MHSc
Professor
Division of Gynecologic Oncology
Department of OB/GYN
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Call to Action and Reflection: Inclusive, Compassionate, and High-Quality Healthcare for Transgender Individuals

support@deceraclinical.com (Nelson F. Sanchez MD) — Fri, 13 May 2022 20:30:00 +0000

In this episode for all healthcare professionals and any patient-facing clinical staff, Nelson F. Sanchez, MD, shares key insights on the need for equitable, compassionate healthcare for transgender individuals, along with practical guidance based on his clinical experience caring for these patients. Topics include:

Communication and physical exam skills
Specific clinical care needs of transgender individuals related to transition
Creating an inclusive and welcoming environment for transgender patients and healthcare workers
Increasing access to clinical trials for transgender individuals
Support for transgender-identified healthcare professionals

Presenter:

Nelson F. Sanchez, MD
Associate Professor of Medicine
Department of Medicine
Weill Cornell Medicine
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience

support@deceraclinical.com (Decera Clinical Education) — Mon, 2 May 2022 20:30:00 +0000

In this episode, Pharmacist Olivia Buckoski shares her experience undergoing medical and social transition and offers advice from the perspective of both a transgender person and healthcare professional on caring for transgender individuals. Topics include:

Importance of educating entire care team about needs of transgender individuals, starting with the waiting room
Specific advice for the exam room
Pharmacy and adherence considerations with hormone therapy
Examples of uninformed care

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials

support@deceraclinical.com (Jyoti Patel MD, Ani Balmanoukian MD) — Fri, 15 Apr 2022 19:10:00 +0000

In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03, and SKYSCRAPER-05.

Presenters:

Jyoti D. Patel, MD
Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Ani Balmanoukian, MD
Director of Thoracic Oncology
Medical Oncology
The Angeles Clinic and Research Institute,
a Cedars-Sinai Affiliate
Los Angeles, California

Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/38qVCH7

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

support@deceraclinical.com (Jyoti Patel MD, Diwakar Davar MD) — Thu, 7 Apr 2022 18:35:00 +0000

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.

Presenters:

Diwakar Davar, MD
Assistant Professor, Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/3r9BLmB

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

Wed, 6 Apr 2022 17:00:00 +0000

In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:

Current use of regorafenib and TAS-102 monotherapy
Combination therapy with regorafenib and PD-1 inhibitors
Adding bevacizumab to TAS-102

Presenters:

Nilofer S. Azad, MD
Professor, Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Kanwal Raghav, MD
Associate Professor, GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Follow along with the slideset:
https://bit.ly/3NLejWe

Link to full program:
https://bit.ly/33yrIyh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Thu, 31 Mar 2022 21:15:00 +0000

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
What is the optimal therapy for a patient with del(17p) CLL?
When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
What are best practices in the use of BTK inhibitors for patients with MCL?
How can BTK inhibitor resistance occur?
How might investigational noncovalent BTK inhibitors be used should they be approved?
What are key adverse events with BTK inhibitors?

Presenters:

Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology
Willamette Valley Cancer Institute
Eugene, Oregon

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5.

Link to full program:
https://bit.ly/3NEpsYQ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma

Mon, 21 Mar 2022 18:00:00 +0000

In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include:

Initial diagnosis
Biomarker testing to guide treatment with immunotherapies and targeted agents
Adverse event management
Strategies for counseling patients

Presenters:

Christine Chio, PharmD, BCOP
Clinical Ambulatory GI Oncology Pharmacist
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts

Lipika Goyal, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Caroline Kuhlman, NP
Department of Gastrointestinal Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Link to the full program on the CCO website:
https://bit.ly/3JGDBCk

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes

Mon, 14 Mar 2022 20:30:00 +0000

In this podcast episode, Amy DeZern, MD, MHS, Daniel Pollyea, MD, MS, and Amer Zeidan, MBBS, discuss challenging cases in MDS, including

Treatment for MDS after ESA failure
Strategies for patients with intermediate- or high-risk MDS
Luspatercept therapy in MDS
MDS case challenges

Link to full program, including downloadable slidesets:
https://bit.ly/3tYwcYu

Presenters:
Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Daniel Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Amer Zeidan, MBBS
Associate Professor, Internal Medicine
Hematology
Yale University
New Haven, Connecticut

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis

Thu, 10 Mar 2022 21:35:00 +0000

In this episode, Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky discuss incorporating KIT-targeted therapies into management of patients with advanced systemic mastocytosis. Topics include:

Diagnosis and prognosis of advanced systemic mastocytosis
Clinical trial data on efficacy of avapritinib and midostaurin
Monitoring for and managing key toxicities with avapritinib, including cognitive dysfunction

Presenters:

Prithviraj Bose, MD
Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD
Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, Texas

Ilene A. Galinsky, NP
Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches

Fri, 25 Feb 2022 21:30:00 +0000

In this episode, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on:

Follicular lymphoma
Marginal zone lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Posttransplant lymphoproliferative disorder

Presenters:

Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Link to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:
https://bit.ly/3tb47wU

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TKIs for Advanced HCC in the Second Line and Beyond

Tue, 22 Feb 2022 17:00:00 +0000

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include:

Available agents for the management of advanced hepatocellular carcinoma in the second line
The current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinoma
Ongoing clinical trials in the second-line setting

Presenters:

Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain

Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine
Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin und Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Directions With PARP Inhibitors in Pancreatic Cancer

support@deceraclinical.com (Naureen Starling MD FRCP, Eileen M. O’Reilly MD) — Mon, 21 Feb 2022 18:35:00 +0000

In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

Current treatment landscape and testing in the United States vs the United Kingdom
Testing for molecular subgroups beyond BRCAm
Using PARP inhibitors in earlier stages of the disease
Learning from other cancers, such as prostate, breast, and ovarian

Presenters:

Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York, USA

Naureen Starling, MD, FRCP
Associate Director of Clinical Research
Department of GI Cancers
Consultant Medical Oncologist, GI Cancers
The Royal Marsden Hospital
London, United Kingdom

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program:
https://bit.ly/3s6AnSz

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples

Fri, 18 Feb 2022 22:40:00 +0000

In this episode,Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases.

Smoldering myeloma
Induction therapy for autologous stem cell transplant–eligible patients
First-line approaches for autologous stem cell transplant–ineligible patients
Treatment after first relapse
Selecting therapy for heavily pretreated myeloma

Presenters:

Brian G.M. Durie, MD
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Link to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and treatment resource guide.

https://bit.ly/3JJbWk9

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Advances in Immune Thrombocytopenia

Mon, 7 Feb 2022 21:10:00 +0000

In this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc,provide expert insights on immune thrombocytopenia management, along with addressing frequently asked questions from a live CCO symposium. Topics include:

New and emerging therapeutic options
Special patient populations, including children
The management of immune thrombocytopenia
COVID-19 vaccinations and immune thrombocytopenia

Presenters:

Keith R. McCrae, MD
Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA

Nichola Cooper, MD
Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College
London, United Kingdom

Rachael Grace, MD, MMSc
Associate Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA

Content based on an online CME program supported by an educational grant from Amgen; Dova Pharmaceuticals, Inc.; and Sanofi Genzyme.

Advances in Immune Thrombocytopenia:
https://bit.ly/3gzykzy

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Precision Medicine for aTTP: Expert Answers to Your Questions

support@deceraclinical.com (Ara Metjian MD, Marshall Mazepa MD, Paul Coppo MD) — Tue, 1 Feb 2022 20:05:00 +0000

In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including:

Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phase
Data for caplacizumab in pediatric patients with aTTP
Initiating rituximab after completion of plasma exchange
International Society on Thrombosis and Haemostasis guideline recommendations against using aspirin
Triggers of aTTP episodes aside from infection
Effect of COVID-19 vaccines and COVID-19 infections on aTTP onset or relapse

Presenters:

Ara Metjian, MD
Associate Professor
Division of Hematology
Department of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Paul Coppo, MD, PhD
Professor of Hematology
Hematology Department, AP-HP
Sorbonne University
Paris, France

Marshall Mazepa, MD
Assistant Professor of Medicine
Division of Hematology, Oncology, and Transplantation
University of Minnesota
Minneapolis, Minnesota

Link to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and healthcare professional resource guide:
https://bit.ly/3J1fcad

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions

Mon, 31 Jan 2022 22:30:00 +0000

In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:

Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCL
Managing relapsed mycosis fungoides after allogeneic SCT
Experience with ALK inhibition in ALCL with central nervous system metastases
Managing refractory pruritus in CTCL
Role of PI3K inhibitors in frontline and relapsed/refractory PTCL
When to consider SCT in CTCL cycling through monotherapies

Presenters:

Steven M. Horwitz, MD
Member
Memorial Sloan Kettering Cancer Center
Attending Physician
Memorial Hospital
Professor of Medicine
Weill Cornell Medical College
New York, New York

Francine Foss, MD
Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Barbara Pro, MD
Professor of Medicine
Division of Hematology/Oncology
Northwestern University
Chicago, Illinois

Link to the complete program, including downloadable slidesets, an expert commentary, and on-demand webcast, and healthcare professional resource guide:
https://bit.ly/3AKJE5s

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease

Wed, 26 Jan 2022 17:00:00 +0000

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:

Testing for targetable biomarkers
Talking with patients about biomarker testing
Frontline therapy for EGFR-positive NSCLC
Resistance to front-line osimertinib
Treatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecan
HER3 protein testing
Pathology considerations
Nursing considerations
Interdisciplinary communication

Presenters:

Conor Ernst Steuer, MD
Assistant Professor
Department of Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Frank Schneider, MD
Associate Professor of Pathology
Department of Pathology and Laboratory Medicine
Director, Cancer Tissue and Pathology Shared Resource
Winship Cancer Institute
Emory University
Atlanta, Georgia

Elise Hitron, MSN, FNP-C
Adjunct Instructor
School of Nursing
Phase I Clinical Trials Nurse Practitioner
Winship Cancer Institute
Emory University
Atlanta, Georgia

Supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including a series of short interactive virtual presentations with downloadable slidesets on EGFR-mutated advanced NSCLC, including the evolving role of HER3 in the setting of EGFR TKI resistance:
https://bit.ly/3G32Jkm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

Fri, 14 Jan 2022 22:00:00 +0000

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include:

Which patients should have pharmacokinetic-guided therapy?
Toxicities with PEGylated extended half-life products
Factor VIII and bone health
Factor VIII peaks, thrombotic risk, and cardiovascular disease
Choosing between extended half-life products and emicizumab for active patients
Role of fitusiran in the treatment paradigm if approved

Presenters:
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Mark Reding, MD
Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director
Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Guy A. Young, MD
Professor of Pediatrics
Director, Hemostasis and
Thrombosis Center
Children’s Hospital Los Angeles
University of Southern California
Keck School of Medicine
Los Angeles, California

Link to full program, including downloadable slidesets, expert commentary, and on-demand webcast:
https://bit.ly/3zZwP6G

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

support@deceraclinical.com (Sarah M Tinsley PhD APRN AOCN) — Mon, 10 Jan 2022 18:00:00 +0000

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:

Approved and emerging treatment options for FLT3-mutated AML
Management of adverse events associated with FLT3 inhibitors
Therapies for IDH1- and IDH2-mutated AML
Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors

Presenters:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations

support@deceraclinical.com (Ashley Leak Bryant PhD RN OCN FAAN) — Mon, 10 Jan 2022 18:00:00 +0000

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses therapeutic options for younger, fit patients with AML and no targetable mutations. Topics include:

Induction chemotherapy and consolidation therapy
Use of gemtuzumab ozogamicin
Management of sinusoidal obstruction syndrome
Nursing considerations for younger, fit patients with AML

Presenter:

Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Secondary AML and Emerging Therapies for AML

support@deceraclinical.com (Sarah M Tinsley PhD APRN AOCN) — Mon, 10 Jan 2022 18:00:00 +0000

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinical trials for AML. Topics include:

Liposomal cytarabine plus daunorubicin for secondary AML
An overview of emerging immune-based strategies for AML
Evidence on immune-based therapies, including agents targeting CD47, TIM3, and bispecific antibodies

Presenter:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy

support@deceraclinical.com (Ashley Leak Bryant PhD RN OCN FAAN) — Mon, 10 Jan 2022 17:55:00 +0000

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for intensive chemotherapy, with a focus on the nursing perspective. Topics include:

An overview of AML
Identifying patients unfit for intensive therapy
Treatment options for unfit patients including venetoclax combinations
Adverse event profiles of treatment options
Nursing considerations for managing patients with AML unfit for intensive therapy

Presenters:

Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications

support@deceraclinical.com (Sarah Tinsley PhD APRN AOCN) — Wed, 22 Dec 2021 22:00:00 +0000

In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R) myelodysplastic syndromes (MDS) with a focus on the nursing perspective. Topics include:

Current and ongoing clinical trials in the higher-risk and R/R MDS setting
Therapies surrounding transplant
Nursing considerations for managing a patient with higher risk and/or R/R MDS

Presenters:

Sarah Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications

support@deceraclinical.com (Ashley Leak Bryant PhD RN OCN FAAN) — Wed, 22 Dec 2021 22:00:00 +0000

In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with a focus on the nursing perspective. Topics include

Risk scoring and treatment algorithms
Current and ongoing clinical trials in the lower-risk MDS setting
Adverse event profiles of current treatment options
Nursing considerations for managing a patient with lower-risk MDS

Presenters:

Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

support@deceraclinical.com (Chiara Cremolini MD PhD, Teresa Macarulla MD PhD) — Fri, 17 Dec 2021 23:00:00 +0000

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:

Transitioning from second- to third-line therapy
Factors in selecting among available therapies
Key predictors of improved outcomes with regorafenib vs TAS-102

Presenters:

Chiara Cremolini, MD, PhD
Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Professor
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy

Teresa Macarulla, MD, PhD
Medical Oncologist
Head, Gastrointestinal and Endocrine Tumors Unit
Division of Medical Oncology
Vall d´Hebrón Institute of Oncology
Barcelona, Spain

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Follow along with the slideset:
https://bit.ly/3FjekMo

Link to full program:
https://bit.ly/33yrIyh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Evolving Role of TKIs in First-line Treatment of Advanced HCC

Tue, 14 Dec 2021 16:30:00 +0000

In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:

Atezolizumab plus bevacizumab as the current standard of care
Contraindications to atezolizumab plus bevacizumab
The current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinoma
Ongoing clinical trials in the first-line setting

Presenters:

Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, NY
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain

Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine, Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin and Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers

support@deceraclinical.com (Nicole Concin MD PhD) — Tue, 23 Nov 2021 21:30:00 +0000

In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:

Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer
Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancer
Results from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancer

Presenters:

Nicole Concin, MD, PhD
Professor
Department of Gynaecology and Obstetrics
Medical University Innsbruck
Innsbruck, Austria
Consultant in Gynaecological Oncology
Department of Gynaecology and Gynaecologocial Oncology
KEM Evang. Kliniken Essen-Mitte
Essen, Germany

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/30PjPnl

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer

Tue, 23 Nov 2021 19:10:00 +0000

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:

Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
Second-line therapeutic options after disease progression on an immunotherapy-based regimen
Immunotherapy in patients with advanced NSCLC and brain metastases
Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response

Presenters:

Julie Brahmer, MD, MSc
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS
Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.

Follow along with the PDF:
https://bit.ly/31aRRmd

Link to full program:
https://bit.ly/3CLC0Hd

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

support@deceraclinical.com (George D. Demetri MD, Alexander Drilon MD) — Tue, 9 Nov 2021 21:00:00 +0000

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

Mechanisms of acquired resistance to TRK inhibitor therapy
Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
Safety profiles of first- vs second-generation TRK inhibitors

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slides:
https://bit.ly/2YFIPfr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

Tue, 2 Nov 2021 21:20:00 +0000

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

Presenters:

Jean-Yves Blay, MD, PhD
Professor of Medical Oncology
Department of Medicine
Centre Leon Berard
Lyon, France

Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape

Tue, 26 Oct 2021 20:30:00 +0000

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

Importance of germline and somatic testing
Adverse events associated with PARP inhibitors
Maintenance therapy in pancreatic cancer

Presenters:

Philip Agop Philip, MD, PhD, FRCP
Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Elena Gabriela Chiorean, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program:
https://bit.ly/3jEehCc

Link to associated downloadable PDF:
https://bit.ly/3nSfTcR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

support@deceraclinical.com (Kanwal Raghav MD MBBS, Rachel Riechelmann MD PhD) — Thu, 21 Oct 2021 20:00:00 +0000

In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

Individualizing therapy
Clinical data and experience informing optimal dosing
Key adverse events

Presenters:

Kanwal Raghav, MD, MBBS
Associate Professor, Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rachel Riechelmann, MD, PhD
Head, Clinical Oncology Department
Medical Oncologist
AC Camargo Cancer Center
Sao Paulo, Brazil

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Link to full program:
https://bit.ly/3aVXplL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

First-Generation TRK Inhibitors: Clinical Evidence and Indications

support@deceraclinical.com (George D Demetri MD, Alexander Drilon MD) — Fri, 15 Oct 2021 20:15:00 +0000

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:

Basket trials leading to FDA approvals of larotrectinib and entrectinib
Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
Sequencing treatment with TRK inhibition in patients with solid tumors
Clinically relevant similarities and differences between larotrectinib and entrectinib

Presenters:

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slidesets:
https://bit.ly/2YFIPfr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm

Thu, 14 Oct 2021 21:00:00 +0000

In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:

Maintenance therapy in ovarian cancer
SOLO1, PRIMA, PAOLO-1 clinical data
Role of bevacizumab in treatment of ovarian cancer

Presenters:
Nicoletta Colombo, MD
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Philipp Harter, MD, PhD
Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Content based on an online CME program supported by an educational grant from AstraZeneca.

New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy
https://bit.ly/3aF8Lui

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A

support@deceraclinical.com (Guy A Young MD) — Fri, 8 Oct 2021 20:15:00 +0000

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:

Overcoming challenges to adherence
Choice of standard vs extended half-life factor VIII vs emicizumab
Safety and efficacy data with emicizumab

Presenter:

Guy A. Young, MD
Professor of Pediatrics
Director, Hemostasis and Thrombosis Center
Children’s Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Link to full program:
https://bit.ly/3FxrVk2

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rationale for NTRK Testing in Patients With Cancer

support@deceraclinical.com (Alexander Drilon MD, George D. Demetri MD) — Fri, 8 Oct 2021 20:00:00 +0000

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:

Differences between NTRK fusions vs gene mutations
Frequency of NTRK fusions by age and tumor type
When to test patients for NTRK fusions and interpreting reports
Methods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsy

Presenters:

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program:
https://bit.ly/2YFIPfr

Link to slideset based on this podcast:
https://bit.ly/3amgU6w

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer

Thu, 7 Oct 2021 20:20:00 +0000

In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including:

How to select between GnRH agonists and antagonists for initial androgen deprivation therapy?
How should androgen receptor inhibitors be incorporated into treatment paradigms for nonmetastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer?
How should patients with prostate cancer and bone density issues be managed?
How should nonmetastatic and metastatic prostate cancer be classified in light of novel imaging modalities, and how does this affect treatment?

Presenters:

Daniel W. Lin, MD
Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Alicia K. Morgans, MD, MPH
Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

David F. Penson, MD
Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

Content based on an online CME program supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Myovant Sciences Ltd, and Pfizer, Inc.

Link to full program:
https://bit.ly/3iFCis5

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

Wed, 29 Sep 2021 20:35:00 +0000

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:

Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor
A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapy
A preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
Quality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancer

Presenters:

Prof. Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Bernard Doger de Spéville, MD, PhD
Medical Oncologist
START-Madrid, Early Phase Clinical Trials Unit
Hospital Fundación Jiménez Díaz
Madrid, Spain

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/3dAttwi

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma

Tue, 28 Sep 2021 20:00:00 +0000

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease.

Link to full program:
https://bit.ly/3ogPjMo

Follow along with the downloadable slideset:
https://bit.ly/2XYNIzt

Presenters:

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
Professor of Medicine
NYU Grossman School of Medicine
New York, New York

Allison Betof Warner, MD, PhD
Assistant Member
Assistant Attending Physician
Melanoma Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Hussein Tawbi, MD, PhD
Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

support@deceraclinical.com (Domenica Lorusso MD PhD, Alexandra Leary MD PhD) — Tue, 21 Sep 2021 20:30:00 +0000

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:

A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR status
A subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapy
Data from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancer
An exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparib
A post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs >4 cycles of platinum-based chemotherapy
Highly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator’s choice chemotherapy in women with cervical cancer

Presenters:

Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/3dAttwi

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

Tue, 24 Aug 2021 20:30:00 +0000

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:

Treatment after first relapsed
Optimal use of CAR T-cell therapy
When to use selinexor and belantamab mafodotin
COVID-19 vaccinations for patients with myeloma

Presenters:

Paul G. Richardson, MD
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Peter M. Voorhees, MD
Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.

Link to full program:
https://bit.ly/2UIhXcL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Thu, 19 Aug 2021 20:20:00 +0000

In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:

How the experts currently use CDK4/6 inhibitors in clinical practice
Clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021
Strategies for counseling patients receiving CDK4/6 inhibitors

Presenters:

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.
Professor of Oncology and Pharmacology
Director, Mayo Clinic Breast Cancer SPORE
Co-Leader, Women's Cancer Program, Mayo Clinic Cancer Center
Co-Chair, Mayo Breast Disease Group
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Link to the full program:
bit.ly/3kaJKeC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Essential Biomarker Testing in GI Cancers

support@deceraclinical.com (John L. Marshall MD) — Wed, 18 Aug 2021 21:15:00 +0000

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:

Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
Colon cancer: RAS, BRAF, and HER2
Gastric cancer: PD-L1, HER2, and more
Pancreatic cancer: BRCA
Biliary cancers: FGFR and IDH1
Liquid biopsies
When to test

Presenter:

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.

Link to full program:
https://bit.ly/3j4hV8J

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

Thu, 5 Aug 2021 20:30:00 +0000

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:

Clinical role of Ki-67 testing
Core biopsies for identifying potential benefit with neoadjuvant endocrine therapy
Combining CDK4/6 inhibition with tamoxifen

Presenters:

Javier Cortes, MD, PhD
Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen R. D. Johnston, MA, FRCP, PhD
Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F Smith Center for Women’s Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy
Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including downloadable slides and associated Podcast Pearls PDF:
https://bit.ly/37tfvtj

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

support@deceraclinical.com (Alicia K Morgans MD MPH, Karim Fizazi MD PhD) — Fri, 30 Jul 2021 20:30:00 +0000

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:

Updated safety and patient preference data from the ARAMIS and ODENZA trials
Choice of apalutamide, darolutamide, and enzalutamide
Counseling patients on adverse events
Managing patients with asymptomatic nonmetastatic CRPC

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France

Alicia K. Morgans, MD, MPH
Associate Professor
Division of Oncology
Department of Medicine
Northwestern University
Chicago, Illinois

Link to full program, including downloadable slides:
https://bit.ly/36IEnNE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Serious Adverse Events Associated with BTK Inhibitor Treatment

support@deceraclinical.com (Amy Goodrich RN, Amy Goodrich RN MSN CRNP-AC) — Tue, 27 Jul 2021 20:30:00 +0000

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

Atrial fibrillation
Cardiac toxicity
Musculoskeletal AEs
Managing risk of infections

Presenter:

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management

support@deceraclinical.com (Sandra E Kurtin PhD ANP-C AOCN, Sandra E Kurtin) — Tue, 27 Jul 2021 20:25:00 +0000

In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include:

Patient adherence to oral medications
Lifestyle changes
Monitoring, recording, and reporting of AEs
The role of the nurse
The role of the patient
AE management

Presenter:

Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions

support@deceraclinical.com (Sandra E. Kurtin PhD ANP-C AOCN) — Tue, 27 Jul 2021 20:20:00 +0000

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:

Pharmacokinetics
Drug metabolism
Drug–drug interactions
Drug–food interactions
The role of CYP enzymes
Foods to avoid
Medication review

Presenter:

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications

support@deceraclinical.com (Decera Clinical Education) — Fri, 23 Jul 2021 20:30:00 +0000

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:

Rationale for inhibiting BTK
MOA of BTK inhibitors
Approved BTK inhibitors
Recent clinical trial findings

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Presenter:

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Adverse Events Associated with BTK Inhibitor Treatment

support@deceraclinical.com (Amy Goodrich RN MSN CRNP-AC) — Fri, 23 Jul 2021 20:30:00 +0000

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:

BTK inhibitor selectivity
BTK inhibitor adverse event profiles
Ibrutinib intolerance
Management of common adverse events

Presenter:

Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer

support@deceraclinical.com (Bertrand Tombal MD PhD, Chris Parker MD) — Tue, 20 Jul 2021 22:00:00 +0000

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:

Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC

Presenters:

Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom

Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium

Link to full program, including downloadable slides:
https://bit.ly/36IEnNE

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies

support@deceraclinical.com (Donna Catamero, Donna Catamero ANP-BC OCN CCRC) — Mon, 19 Jul 2021 20:30:00 +0000

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.

Presenter:

Donna Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to HCP Questions on CAR T-Cell Therapy

support@deceraclinical.com (Noopur Raje MD, Caron A Jacobson MD, Jae H Park MD) — Mon, 19 Jul 2021 20:30:00 +0000

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:

At what time in the treatment journey should CAR T-cell therapy be considered?
How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?
How is CAR T-cell therapy best used for multiple myeloma?
What qualities of bridging therapy are most preferred?
When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?
How are steroids optimally used in managing CAR T-cell therapy–related toxicities?

Presenters:

Caron A. Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Jae H. Park, MD
Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/3BfbEOf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide

support@deceraclinical.com (Tiffany Richards, Tiffany Richards PhD ANP-BC AOCNP) — Fri, 16 Jul 2021 21:00:00 +0000

In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.

Presenter:

Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs

Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment Options for Patients With Multiple Myeloma After First Relapse

support@deceraclinical.com (Charise Gleason MSN NP-BC AOCNP) — Wed, 14 Jul 2021 20:30:00 +0000

In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include:

Strategies for monitoring for disease progression
Disease, therapy, and patient considerations for treatment selection at first relapse
Nursing implications and supportive care considerations for patients receiving therapy for relapsed disease

Presenter:

Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Emory University
Atlanta, Georgia

CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs

Link to full program, including downloadable slidesets:
https://bit.ly/3ee9Ivs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Caring for Patients With Newly Diagnosed Multiple Myeloma

support@deceraclinical.com (Decera Clinical Education) — Wed, 14 Jul 2021 20:30:00 +0000

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include:

IMWG criteria for diagnosing smoldering and active myeloma
Risk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS staging
Individualizing initial treatment for ASCT-ineligible myeloma
Selecting optimal initial treatment for ASCT-eligible myeloma

Presenter:

Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs

Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Precision Medicine in Gynecologic Cancers: Expert Answers to Your Questions

Mon, 12 Jul 2021 20:45:00 +0000

In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:

Adding bevacizumab to chemotherapy in frontline endometrial cancer
Lenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancer
PARP inhibitor maintenance in ovarian cancer
Bevacizumab with or without PARP inhibitors in ovarian cancer

Presenters:

Linda R. Duska, MD, MPH
Lawrence W. Penniston MD Family Professor in Women’s Oncology Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas

Leslie Randall, MD, MAS
Diane Harris Wright Professor and Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3e6pZCM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

support@deceraclinical.com (Brian D Weiss MD, Scott R Plotkin MD PhD) — Mon, 12 Jul 2021 20:30:00 +0000

In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:

Whole exome sequencing for diagnosis
When to treat asymptomatic tumors
Genetic testing of family members
Choosing a MEK inhibitor
Supportive care for acneiform rash
Other RAS pathway inhibitors

Presenters:

Scott R. Plotkin, MD, PhD
Executive Director
Pappas Center for Neuro-Oncology
Professor of Neurology
Harvard Medical School
Boston, Massachusetts

Brian D. Weiss, MD
Clinical Professor of Pediatrics
Cancer and Blood Diseases Institute Division of Oncology
Medical Director
Solid Tumor Program
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3AXckHQ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

Wed, 30 Jun 2021 20:30:00 +0000

In this episode, Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including:

Germline and somatic mutation testing
PARP inhibition in earlier stage disease
PARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapy
PARP inhibition in taxane-sensitive patients

Presenters:

Wassim Abida, MD, PhD
Assistant Member
Assistant Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Joaquin Mateo, MD, PhD
Group Leader
Prostate Cancer Translational Research
Vall d'Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3h1T5oR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions

support@deceraclinical.com (David Kaplan MD MSc, Thomas Karasic MD) — Tue, 29 Jun 2021 20:20:00 +0000

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:

Current systemic therapy standards of care for patients with advanced HCC
Use of single-agent immune checkpoint inhibitor therapy in the first-line setting
Assessing bleeding risk
Using immunotherapy in patients with active HBV or HCV infections

Presenters:

David Kaplan, MD, MSc
Associate Professor
Perelman School of Medicine
University of Pennsylvania
Director of Hepatology
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania

Thomas Karasic, MD
Assistant Professor of Medicine
Department of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
https://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Data From ASCO 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer

Thu, 24 Jun 2021 20:30:00 +0000

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:

Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancer
Updated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)
Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancer
Results from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancer
Highly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancer
A post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1
Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancers

Presenters:

Melissa M. Hardesty, MD, MPH
Affiliate Associate Professor
OB/GYN/GYN Oncology
University of Alaska Anchorage
Gynecologic Oncologist and Managing Partner
Alaska Women’s Cancer Care
Anchorage, Alaska

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3dAttwi

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions

support@deceraclinical.com (Saad Usmani MD, Suzanne Lentzch MD PhD) — Thu, 17 Jun 2021 20:30:00 +0000

In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:

Selecting optimal triplet regimen after first relapse
Sequencing treatment options after multiple relapses
Managing patient expectations when selecting treatments
Emerging treatment options for R/R MM

Presenters:

Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Saad Z. Usmani, MD, MBA, FACP
Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina

Supported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.

Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3gjr62p

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer

Wed, 19 May 2021 20:40:00 +0000

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:

Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC
Incorporating newly approved immunotherapies into practice
Evolving guidelines and recommendations for biomarker testing
RNA- vs DNA-based next-generation sequencing
Interpretation of NGS results
Use of frontline TKI therapy for patients with CNS metastases
Future role of KRAS inhibitors in the treatment of advanced NSCLC
Improving rates of biomarker testing in lung cancer

Presenters:

Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen V. Liu, MD
Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Supported by educational grants from Amgen; Lilly; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3npjyyb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Tue, 18 May 2021 21:00:00 +0000

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:

Biopsies and biomarker testing considerations
Tumor heterogeneity and targeting of brain metastases
Liquid biopsies
Sequencing of ADCs following previous therapy
Toxicity management

Presenters:

Egbert F. Smit, MD, PhD
Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands

David Planchard, MD, PhD
Head of Thoracic Group
Department of Medical Oncology
Institute Gustave Roussy
Villejuif, France

Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.

Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com)

Link to full program:
https://bit.ly/3fr2G6G

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Immunotherapy for Advanced HCC: Case Series

support@deceraclinical.com (Lipika Goyal MD, Amit G. Singal MD MS) — Mon, 17 May 2021 21:00:00 +0000

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:

First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding risk
First-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding risk
First-line systemic treatment for a patient with Child-Pugh B liver function
Second-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumab
Management of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitor

Presenters:

Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
https://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany

support@deceraclinical.com (Georgios Gakis MD, Mario Wolfgang Kramer MD PhD) — Thu, 13 May 2021 20:20:00 +0000

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:

Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
When to consider first-line treatment with immune checkpoint inhibitor monotherapy
Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy

Presenters:

Georgios Gakis, MD
Professor of Urology, Staff Urologist
University Hospital of Würzburg
Würzburg, Germany

Mario Wolfgang Kramer, MD, PhD
Consultant Urologist
Vice Director, Urology
University Hospital Schlewig-Holstein Campus Lübeck
Lübeck, Germany

Content based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand webcast:
https://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond

support@deceraclinical.com (Alison Birtle MD FRCP FRCR, Ignacio Durán MD PhD) — Tue, 4 May 2021 20:30:00 +0000

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies

Presenters:

Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom

Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.

Link to full program:
http://bit.ly/3cf28jH

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer

support@deceraclinical.com (Joleen Hubbard MD, John Marshall MD) — Wed, 28 Apr 2021 20:15:00 +0000

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:

Key data supporting the clinical use of these agents
Optimal sequencing and timing of use
Dosing considerations
Key adverse events

Presenters:

Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Link to full program: BITLY NEEDED

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Questions on Contemporary Management of Multiple Myeloma

Thu, 22 Apr 2021 20:20:00 +0000

In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:

Approaches for managing smoldering multiple myeloma
Insights on new strategies for managing newly diagnosed multiple myeloma
Incorporating newly approved agents in the frontline and early relapse setting
Choosing and sequencing BCMA-targeted therapies
Managing patients with refractory multiple myeloma

Presenters:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.

Link to full program, including downloadable slidesets and expert commentaries:
https://bit.ly/39MWNid

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates

support@deceraclinical.com (Joaquin Mateo MD PhD, Karim Fizazi MD PhD) — Mon, 19 Apr 2021 20:25:00 +0000

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:

PARP inhibitors combined with androgen receptors
Phase III trials of PARP inhibitors with androgen receptor–directed therapy
PARP inhibitors combined with immunotherapy
PARP inhibitors and DNA damaging agents

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France

Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain

Content is part of an online program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

support@deceraclinical.com (Karim Fizazi MD PhD, Joaquin Mateo MD PhD) — Thu, 15 Apr 2021 20:15:00 +0000

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:

Possible synergy between PARP inhibitors and androgen receptor–directed therapy
Rationale for PARP inhibitors and immunotherapy combinations
Benefits and challenges of combining DNA damaging agents and PARP inhibitor

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France

Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain

Content is part of an online program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer

support@deceraclinical.com (Jubilee Brown MD, Ursula Matulonis MD) — Tue, 6 Apr 2021 20:15:00 +0000

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:

Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer

Presenters:

Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3dAttwi

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Questions on PARP Inhibition for Prostate Cancer

support@deceraclinical.com (Neal D. Shore MD FACS, Charles J. Ryan MD) — Tue, 6 Apr 2021 20:00:00 +0000

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:

Germline and somatic mutation testing
Managing adverse events with PARP inhibitors
Resistance to PARP inhibitors
Implications of monoallelic vs biallelic BRCA mutations
ATM mutations and PARP inhibitor sensitivity

Presenters:

Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/2P31ZqF

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL

support@deceraclinical.com (Jeremy S. Abramson MD MMSc) — Fri, 26 Mar 2021 20:30:00 +0000

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:

Approved and Investigational Targeted Therapeutics for CLL
Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
Treatment for Older Patients With Hodgkin Lymphoma

Presenters:

Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.

Link to full program:
https://bit.ly/3tyQ9nG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer: Global Insights on Evolving Practice Standards

support@deceraclinical.com (Matthew Gubens MD MS, Enriqueta Felip MD PhD) — Thu, 25 Mar 2021 20:00:00 +0000

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:

Biomarker testing and strategies
Optimal first-line therapy in patients with NSCLC
Management of patients with CNS disease
Selecting therapy for patients with noncanonical mutations
Management strategies after progression on first-line EGFR TKI therapy
Selecting therapy for patients with early stage disease

Presenters:

Enriqueta Felip, MD, PhD
Head, Thoracic Oncology Unit
Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain

Matthew Gubens, MD, MS
Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://bit.ly/2PpFFHM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Targeting FGFR in Urothelial Cancer and Beyond

support@deceraclinical.com (Ignacio Durán MD PhD, Alison Birtle MD FRCP FRCR) — Tue, 23 Mar 2021 20:30:00 +0000

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer

Presenters:

Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain

Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom

Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.

Link to full program:
http://bit.ly/3cf28jH

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to HCP Questions on Pancreatic Cancer Treatment

support@deceraclinical.com (Michael J. Pishvaian MD PhD, Rachna Shroff MD) — Mon, 22 Mar 2021 20:30:00 +0000

In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including:

What is your preferred regimen for neoadjuvant therapy in patients with resectable disease?
How do you sequence therapy for patients with metastatic pancreatic cancer?
How can you manage a patient who develops significant diarrhea with FOLFIRINOX?
Are cisplatin and oxaliplatin equally efficacious for patients with BRCA-mutant disease?
How should maintenance olaparib be used?

Presenters:

Michael J. Pishvaian, MD, PhD
Associate Professor of Oncology
Director, Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
NCR Kimmel Cancer Center at Sibley Memorial Hospital
John Hopkins University School of Medicine
Washington, DC

Rachna Shroff, MD
Associate Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Ipsen Group.

Link to full program:
http://bit.ly/314BALT

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma

support@deceraclinical.com (Decera Clinical Education) — Thu, 18 Mar 2021 21:25:00 +0000

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:

How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL?
Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?
How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?
How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?

Presenter:

Frederick L. Locke, MD
Co-Leader
Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director and Medical Director
Immune Cell Therapy Program
Moffitt Cancer Center
Tampa, Florida

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.

Link to full program:
https://bit.ly/3rDeFCV

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Frequently Asked Questions on Emerging Antibody–Drug Conjugates in the Treatment of Advanced Non-Small-Cell Lung Cancer

support@deceraclinical.com (Ross Camidge MD PhD, Joel W. Neal MD PhD) — Wed, 17 Mar 2021 21:15:00 +0000

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC

Presenters:

Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Joel W. Neal, MD, PhD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Content based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .

Link to full program:
http://bit.ly/3twpIyl

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to HCP Questions on CAR T-Cell Therapies in Myeloma and Management of Key Toxicities

support@deceraclinical.com (Noopur Raje MD) — Fri, 12 Mar 2021 22:15:00 +0000

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:

Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?
Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?
What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?
What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?

Presenter:

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.

Link to full program:
http://bit.ly/3rDeFCV

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Highlights From ASH 2020 on Multiple Myeloma

support@deceraclinical.com (Shaji K. Kumar MD, Sagar Lonial MD) — Fri, 12 Mar 2021 21:20:00 +0000

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:

Newly diagnosed multiple myeloma
Relapsed/refractory multiple myeloma
Anti-BCMA therapy: CAR T-cells
Anti-BCMA therapy: bispecific antibodies
Anti-BCMA therapy: antibody–drug conjugates
Novel targeted agents for relapsed/refractory multiple myeloma

Presenters:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Link to the CCO website:
http://bit.ly/30EqUn0

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias

support@deceraclinical.com (Eunice S. Wang MD, Jorge Cortes MD) — Fri, 26 Feb 2021 21:30:00 +0000

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:

The macrophage immune checkpoint inhibitor magrolimab in AML
The STAMP inhibitor asciminib in CML (the ASCEMBL trial)
Optimal dosing for the TKI ponatinib in CML

Presenters:

Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia

Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.

Link to full program and Capsule Summary downloadable slidesets:
https://bit.ly/3tyQ9nG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer

support@deceraclinical.com (Jamie E. Chaft MD) — Wed, 24 Feb 2021 22:00:00 +0000

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:

Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib
An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance
FDG PET/CT adaptive radiotherapy in RTOG 1106
The TALENT study in Taiwan screening nonsmokers for lung cancer

Presenter:

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Content supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
http://bit.ly/2NzE6X6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Argentina

support@deceraclinical.com (José Ignacio Nolazco, Alejandro Nolazco) — Mon, 22 Feb 2021 21:30:00 +0000

In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective.

Presenters:

José Ignacio Nolazco, MD
Urology Fellow
Hospital Universitario Austral
Buenos Aires, Argentina

Alejandro Nolazco, MD
Associate Professor
Department of Urology
Universidad Austral and Universidad Católica Argentina
Buenos Aires, Argentina

Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Key Data From ASH 2020 on Nonmalignant Hematologic Disorders

Wed, 10 Feb 2021 21:20:00 +0000

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:

Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study
Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP
New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B
An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up
Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD
Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD
Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD

Presenters:

Hanny Al-Samkari, MD
Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Sujit Sheth, MD
Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.

Link to full program, including downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3tyQ9nG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms

support@deceraclinical.com (Amy E. DeZern MD MHS, Srdan Verstovsek MD PhD) — Fri, 5 Feb 2021 21:35:00 +0000

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:

3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.

Presenters:

Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Link to full program and Capsule Summary downloadable slidesets:
http://bit.ly/3tyQ9nG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Questions on Contemporary Management of Hemophilia A

Thu, 4 Feb 2021 21:30:00 +0000

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:

Maintaining long-term musculoskeletal health
Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis
Managing combination therapies in older patients with comorbidities
Youngest age at which patients can be considered for emicizumab
Development of resistance to emicizumab
Switching recombinant factor therapies
Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors
Potential clinical role of extending FVIII half-life with BIVV001
Considerations when dosing emicizumab monthly

Presenters:

Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children’s Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Rebecca Kruse-Jarres, MD, MPH
Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington

Content supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.

Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Italy

support@deceraclinical.com (Cora N. Sternberg MD FACP, Guiseppe Procopio MD) — Thu, 4 Feb 2021 21:30:00 +0000

In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer.

Presenters:

Guiseppe Procopio, MD
Head of the Medical Oncology Genitourinary, Istituto Nazionale Tumori
Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy

Cora N. Sternberg, MD, FACP
Professor of Medicine
Department of Hematology/Oncology
Weill Cornell Medicine
New York, New York, USA

Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.

Link to full program, including associated downloadable slidesets and on-demand Webcast: http://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the United States

support@deceraclinical.com (Jonathan E. Rosenberg MD, Petros Grivas MD PhD) — Mon, 1 Feb 2021 21:45:00 +0000

In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:

Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
When to consider first-line treatment with immune checkpoint inhibitor monotherapy
Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy
Monitoring for and managing immune-related adverse events during the COVID-19 pandemic

Presenters:

Petros Grivas, MD, PhD
Associate Professor
Clinical Director, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, Washington, USA

Jonathan E. Rosenberg MD
Attending Physician
Chief, Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York, USA

Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
http://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

An Expert Overview of Immunotherapy for Advanced HCC

support@deceraclinical.com (Lipika Goyal MD, Amit G. Singal MD MS) — Tue, 19 Jan 2021 23:00:00 +0000

Link to CME: Claim Credit

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:

Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
Use of nivolumab ± ipilimumab and pembrolizumab
Emerging immunotherapy combinations currently being investigated in clinical trials
Management of key adverse events with immune checkpoint inhibitors

Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
http://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Spain

Fri, 8 Jan 2021 21:00:00 +0000

In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer.

Presenters:

Félix Guerrero Ramos, MD, PhD, FEBU
Teaching Collaborator
Department of Surgery
Medicine School
Universidad Complutense de Madrid
Attending Urologist
Department of Urology
UroOncology Unit
Madrid, Spain

Óscar Rodríguez-Faba, MD
Urologist
Uro-Oncology
Fundació Puigvert
Barcelona, Catalonia, Spain

Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
http://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Expert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung Cance

support@deceraclinical.com (Laura J. Tafe MD, Nathan Pennell MD PhD) — Mon, 28 Dec 2020 21:20:00 +0000

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:

Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistance
Performing biomarker testing on cytology vs surgical or anatomic pathology specimens
Factors affecting turnaround time when testing liquid biopsy vs tissue specimens
Choice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skipping
Concordance between IHC and FISH or NGS for ALK rearrangements
Use of fluid cytology specimens when testing for fusions in RET or NTRK and MET amplification
Cost considerations with performing multiple single-gene assays vs upfront NGS
Testing for driver mutations in early-stage NSCLC
Developing institutional workflows to enable pathologists to order reflex molecular testing panels

Presenters:

Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
The Geisel School of Medicine at Dartmouth
Hanover, New Hampshire

Content supported by an educational grant from Lilly.

Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy: FAQ

Thu, 24 Dec 2020 00:35:00 +0000

In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.

Presenters:

William G. Wierda, MD, PhD, Program Director
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Content based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.

Link to full program, including associated downloadable slidesets:
http://bit.ly/3mLjeIb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC

support@deceraclinical.com (Helena A. Yu MD, Maria E. Arcila MD) — Mon, 21 Dec 2020 22:45:00 +0000

In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:

Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrence
Biomarker testing in early-stage lung cancer
New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated NSCLC
Interim results from the phase I portion of the CHRYSALIS trial evaluating amivantamab, a bispecific antibody that targets EGFR and MET, in combination with lazertinib, a third-generation EGFR TKI, for the treatment of EGFR-mutated NSCLC
Phase I data on the HER3-directed antibody–drug conjugate patritumab deruxtecan for NSCLC with progression on an EGFR TKI

Presenters:

Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Maria E. Arcila, MD
Pathologist
Director, Diagnostic Molecular Pathology Laboratory
Memorial Sloan Kettering Cancer Center
New York, New York

Content supported by an educational grant from Lilly.

Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Immunotherapy for Advanced HCC: Experts Answer Clinician Questions

support@deceraclinical.com (Lipika Goyal MD, Amit G. Singal MD MS) — Thu, 17 Dec 2020 16:47:50 +0000

Link to CME: Claim Credit

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:

Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
Use of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver function
Use of biomarkers to inform treatment for patients with advanced HCC

Presenters:

Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
https://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom

Fri, 20 Nov 2020 22:15:00 +0000

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:

Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings
Utility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapy
Results from the JAVELIN trial on avelumab maintenance after chemotherapy
When to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapy

Presenters:

Thomas Powles, MBBS, MRCP, MD
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden, MD, PhD
Medical Oncologist and Research Group Leader
Department of Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, the Netherlands

Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.

Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From France

support@deceraclinical.com (Alain Ravaud MD PhD, Marine Gross-Goupil MD PhD) — Thu, 19 Nov 2020 21:35:00 +0000

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer.

Presenters:

Alain Ravaud, MD, PhD
Professor of Medical Oncology
Head of Department of Medical Oncology
Bordeaux University Hospital
Bordeaux, France

Marine Gross-Goupil, MD, PhD
Medical Oncologist
Saint-André Hospital
Bordeaux University Hospital
Bordeaux, France

Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.

Link to full program:
https://bit.ly/3kJC5SL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Molecular Classification of Endometrial Carcinoma in the Clinic Today

support@deceraclinical.com (Ana Oaknin MD PhD, Mansoor Raza Mirza MD) — Wed, 11 Nov 2020 21:30:00 +0000

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer.

Presenters:

Ana Oaknin, MD, PhD
Head of Gynecologic Tumors Unit
Medical Oncology Department
Vall d´Hebron University Hospital
Barcelona, Spain

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology,
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program:
https://bit.ly/3kpJeaG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Advances in Immunotherapy for Endometrial Cancer

support@deceraclinical.com (Mansoor Raza Mirza, Ana Oaknin) — Wed, 11 Nov 2020 21:20:00 +0000

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.

Presenters:

Ana Oaknin, MD, PhD
Head of Gynecologic Tumors Unit
Medical Oncology Department
Vall d´Hebron University Hospital
Barcelona, Spain

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology,
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program:
https://bit.ly/3kpJeaG

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Developments in Acute Leukemias: Expert Answers to Clinician Questions

support@deceraclinical.com (David Marks MD PhD, Stéphane de Botton MD) — Fri, 2 Oct 2020 20:35:00 +0000

In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:

MRD in the management of ALL
Therapy choice for older patients with AML
Optimal use of inotuzumab ozogamicin and blinatumomab for ALL
Use of CAR T-cell therapy for acute leukemias

Content based on an online CME program supported by an educational grant from Pfizer Inc.

Link to full program:
https://bit.ly/3jiCBaD

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Biomarkers in Ovarian Cancer: Expert Discussion of Options for First-line Maintenance Therapy

Fri, 2 Oct 2020 20:35:00 +0000

In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer.

Presenters:

Prof Isabelle Ray Coquard
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Bradley J. Monk MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program:
https://bit.ly/2Scnp2N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Biomarkers in Ovarian Cancer: Expert Discussion of BRCA Testing and Beyond

Fri, 2 Oct 2020 20:25:00 +0000

Listen to Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing for your patients with advanced ovarian cancer.

In this episode, Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing in the management of patients with advanced ovarian cancer. Topics include:

Subtypes of ovarian cancer
BRCA mutation testing
Homologous recombination deficiency testing

Presenters:

Professor Nicoletta Colombo
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program:
https://bit.ly/2Scnp2N

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC

Mon, 21 Sep 2020 20:25:13 +0000

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:

Local therapy in the context of MBC
Choice of therapy after progression on available standards of care
Choice of trastuzumab deruxtecan and tucatinib based on patient presentation
Managing patients with CNS metastases
Managing interstitial lung disease

Presenters:
Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Léon Bérard
Lyon, France

Adam M. Brufsky, MD, PhD
Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Cristina Saura, MD, PhD
Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebron University Hospital
Barcelona, Spain

Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including associated downloadable slidesets:
https://bit.ly/32A1HMb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Art of Medicine: Clinical Considerations for Patients With Advanced RCC

Mon, 21 Sep 2020 20:20:05 +0000

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:

Treating beyond progression with immunotherapy
Management of patients with less common histologic subtypes of RCC
Potential biomarkers for RCC
Adverse event management

Presenters:

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/
Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York

Content based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.

Link to full program:
https://bit.ly/32IS9gx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1

Thu, 17 Sep 2020 20:20:24 +0000

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.

Presenters:

Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies
& Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Nicole Lamanna, MD
Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3

Thu, 17 Sep 2020 20:15:13 +0000

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:

• The impact of COVID-19 on CLL treatment decisions

• The use of anti-CD20 antibodies in combination with BTK inhibitors

• Considerations when recommending BTK inhibitors

• MRD testing in patients with CLL

• The potential impact of targeted therapies on when to start treatment

Presenters:
Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Clinical Considerations for RET Fusion–Positive NSCLC

support@deceraclinical.com (Joshua Bauml MD, Dara L. Aisner MD PhD) — Thu, 17 Sep 2020 20:10:02 +0000

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

Optimal testing for RET fusions
DNA NGS vs RNA NGS
Molecular testing workflows
Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
Common toxicities with new selective RET inhibitors
Interdisciplinary communication between medical oncologists and pathologists

Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado

Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2

Wed, 16 Sep 2020 20:05:06 +0000

Rechallenging patients with venetoclax and BTK inhibitors
Mechanism by which BTK inhibitors may reduce infusion reactions
Risk of secondary malignancies with BTK inhibition
Different cytogenetic findings and adverse event risk

Presenters:

Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions

Mon, 14 Sep 2020 20:20:03 +0000

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:

Optimal use of approved CAR T-cell therapies for lymphoma and ALL
Investigational CAR T-cell therapies for multiple myeloma
Managing CAR T-cell therapy–related toxicities

Presenters:
Michael R. Bishop, MD
Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois

Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief, Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.

Link to full program:
https://bit.ly/3iyt5zQ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Practical Application of Immuno-Oncology in RCC: Expert Discussion of Second-line Therapy and Beyond

Tue, 8 Sep 2020 22:20:06 +0000

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:

• Treatment sequencing with IO and TKI therapies

• Optimizing dose for patients with preexisting toxicities

• Considerations for local control of metastatic sites

• Ongoing clinical trials

Presenters:

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York

Content based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.

Link to full program:
https://bit.ly/32IS9gx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma

Thu, 3 Sep 2020 20:15:04 +0000

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:

• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial

• Selecting therapy for a patient with lenalidomide-refractory disease at first relapse

• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms

• Key findings from the DREAMM2 trial on belantamab mafodotin

• Monitoring and management strategies for ocular toxicity with belantamab mafodotin

Presenters:

Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Paula Rodriguez-Otero, MD, PhD
Associate Professor
Consultant in Hematology
Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain

Prof. Dr. med. Katja Weisel
Deputy Director
II. Medical Clinic and Polyclinic
Department of Oncology and Hematology
Department of Pneumology and Bone Marrow Transplantation
University Medical Center
Hamburg-Eppendorf
Hamburg, Germany

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program, including associated downloadable slidesets:

https://bit.ly/2QRqYuC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments

support@deceraclinical.com (Natalie S. Callander MD, Shaji Kumar MD) — Tue, 1 Sep 2020 20:20:19 +0000

In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.

Presenters:

Natalie S. Callander, MD
Professor of Medicine
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Shaji Kumar, MD
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Content based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.

Link to full program, including associated downloadable slidesets:

https://bit.ly/3gT324y

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy

Mon, 31 Aug 2020 23:00:11 +0000

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:

Choice of first-line therapy
Combinations of targeted agents and immunotherapy
Combinations of immune checkpoint inhibitors
Active surveillance and monitoring
Cytoreductive nephrectomy

Presenters:

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York

Content based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.

Link to full program: https://bit.ly/32IS9gx

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

support@deceraclinical.com (Jennifer R. Brown MD PhD, John Allan MD) — Mon, 31 Aug 2020 20:15:12 +0000

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:

ASPEN: Zanubrutinib vs ibrutinib in WM
OASIS: Ibrutinib, venetoclax, and obinutuzumab in MCL
GHSG HD17: PET-guided therapy in HL
KEYNOTE-024: Pembrolizumab vs brentuximab in HL
ALEXANDER: AUTO3 in DLBCL

Presenters:

Jennifer R. Brown, MD, PhD
Associate Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://bit.ly/3aSfekM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1

Fri, 28 Aug 2020 20:30:22 +0000

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:

Incorporating MET exon 14 testing into standard of care
Comparison of RNA-based and DNA-based NGS platforms
Availability of RNA-based NGS testing around the world
Using FISH to quantify MET copy gain/amplification
Regulatory and clinical differences between new, selective MET inhibitors
Safety profiles of type I vs type II MET inhibitors
Counseling patients on management of peripheral edema, a class effect with MET inhibitor therapy
Insights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapy
Selecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinib

Presenters:
Luis Paz-Ares, MD, PhD
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Content based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

Link to full program, including associated downloadable slidesets:
https://bit.ly/2ExadCf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2

Fri, 28 Aug 2020 20:30:21 +0000

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:

Whether testing for MET exon 14 status should be standard of care
Parallel vs sequential testing by DNA-based vs RNA-based NGS
Co-occurring driver mutations in patients with METex14 mutation–positive NSCLC
Optimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapy
EMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinib

Presenters:
Luis Paz-Ares, MD, PhD
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Link to full program, including associated downloadable slidesets: https://bit.ly/2ExadCf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Immunotherapy in SCLC: FAQ on Current Best Practice and Emerging Therapeutic Strategies

support@deceraclinical.com (Decera Clinical Education) — Thu, 27 Aug 2020 21:30:22 +0000

In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:

Selecting between atezolizumab and durvalumab in the frontline setting
Integration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient care
Which patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line setting
Management of brain metastases in patients with advanced SCLC

Presenters:

Anna F. Farago, MD, PhD
Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Taofeek K. Owonikoko, MD, PhD
Professor
Department of Hematology and
Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Content based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp.

Link to full program, including associated downloadable slidesets: https://bit.ly/3aTzthZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: CLL

support@deceraclinical.com (Decera Clinical Education) — Wed, 26 Aug 2020 21:30:04 +0000

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:

ASCEND: acalabrutinib vs idelalisib plus rituximab or BR
ACE-CL-001: acalabrutinib long-term efficacy
CLL14: Venetoclax plus obinutuzumab
CLARITY: Ibrutinib plus venetoclax
Measurable residual disease (MRD)
Complex karyotypes
Zanubrutinib plus obinutuzumab and venetoclax

John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://bit.ly/3aSfekM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Future Treatment Strategies for Acute Myeloid Leukemia—Emerging Targeted Therapy Combinations and Beyond

support@deceraclinical.com (Decera Clinical Education) — Fri, 14 Aug 2020 21:00:08 +0000

In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:

FLT3 inhibitors crenolanib and quizartinib
Anti-CD47 antibody magrolimab
IMGN632, a CD123 antibody–drug conjugate
Anti-CD70 antibody cusatuzumab
APR-246, targeting the TP53 mutation

Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.

Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions

support@deceraclinical.com (Decera Clinical Education) — Fri, 14 Aug 2020 21:00:07 +0000

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:

Best practices in testing for NTRK fusions in solid tumors
Optimal use of approved TRK inhibitors
Key adverse events with TRK inhibitors and management strategies
Emerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agents

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Pashtoon Kasi, MD
Assistant Professor
College of Medicine and Oncology
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa

Content based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.

Link to full program: https://bit.ly/2PN0BWh

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Improving Outcomes for Patients With CML With TKIs: FAQ Podcast

support@deceraclinical.com (Decera Clinical Education) — Thu, 13 Aug 2020 21:00:06 +0000

In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:

Frontline Management of Chronic-Phase CML
Selection of TKI Based on Goal of Treatment-Free Remission
Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
Changing TKIs due to CML Progression: Second-line Therapy and Future Options

Presenters:
Prof. Dr. med Tim Henrik Brümmendorf
Head
Department of Hematology, Oncology, Hematostaseology, and Stem Cell Transplantation
University Hospital Aachen, RWTH Aachen
Aachen, Germany

Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia, USA

Carlo Gambacorti-Passerini, MD
Professor, Hematology
University Milano Bicocca
Director, Hematology
San Gerardo Hospital
Monza, Italy

Content based on an online CME program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable slidesets:
https://bit.ly/30P8Uaf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types: Answering Clinician Questions

Mon, 10 Aug 2020 21:30:07 +0000

In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:

Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)
Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibition
Neoadjuvant treatment with immune checkpoint inhibitors
Financial considerations when selecting chemotherapy vs immuno-oncology

Presenters:

John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Scot Niglio, MD
Medical Oncologist
Bethesda, Maryland

Content based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.

Link to full program:
https://bit.ly/31vQtqb

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Precision Therapy in Lung Cancer: FAQ on Biomarker Testing and Targeted Therapies

support@deceraclinical.com (Decera Clinical Education) — Mon, 10 Aug 2020 21:30:07 +0000

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:

How to approach discordant results with liquid vs tissue biopsies
Repeating NGS testing at progression
Selecting urgent treatment when molecular results are not yet available
Point mutations in NTRK fusion–positive disease
Selecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKI
Selecting first-line and second-line therapy for ROS1-positive disease
Standard of care for MET-altered disease
Selecting second-line therapy for RET fusion–positive disease after first-line TKI

Presenters:

Edward S. Kim, MD, FACP
Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors

support@deceraclinical.com (Decera Clinical Education) — Mon, 10 Aug 2020 21:30:06 +0000

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:

Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expression
Choosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expression
Leveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumab
STK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapy
Treatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitor
Rechallenging after stopping immune checkpoint inhibitor due to immune-related adverse events

Presenters:

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.